adriandino的个人主页 - 老虎社区

adriandino

adriandino

暂无个人介绍

IP属地：未知

501关注

10粉丝

4主题

0勋章

2021-12-22

Wow

BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>

2021-12-05

Buy

抱歉，原内容已删除

2021-12-03

Up?

Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>

2021-11-12

Liked

Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>

2021-11-04

Oh no

Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>

2021-10-19

Buy buy buy

Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>

2021-10-13

Buy buy buy

Tesla Stock: The Path To $2,500 By 2030<blockquote>特斯拉股票：到2030年将达到2,500美元</blockquote>

2021-10-11

Buy buy buy

抱歉，原内容已删除

2021-09-28

Buy buy buy

抱歉，原内容已删除

2021-09-27

Buy buy buy

抱歉，原内容已删除

2021-09-22

Buy buy buy

抱歉，原内容已删除

2021-09-21

Buy buy buy

抱歉，原内容已删除

2021-09-03

WOW 🥺

抱歉，原内容已删除

2021-08-26

Good

抱歉，原内容已删除

2021-08-07

Buy buy buy

抱歉，原内容已删除

2021-08-05

Buy buy buy

Here's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote>

2021-07-30

Buy buy buy

AMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote>

2021-07-23

Buy buy buy

抱歉，原内容已删除

2021-07-01

Buy buy buy

S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>

2021-06-30

Buy All

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3557838603033373","uuid":"3557838603033373","gmtCreate":1594744580157,"gmtModify":1619438267726,"name":"adriandino","pinyin":"adriandino","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":501,"tweetSize":75,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"93.63%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":"1165830356","repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":2502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608690847,"gmtCreate":1638701123059,"gmtModify":1638701123059,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608690847","repostId":"2188528084","repostType":4,"isVote":1,"tweetType":1,"viewCount":3414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601292988,"gmtCreate":1638531326683,"gmtModify":1638531350519,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Up?","listText":"Up?","text":"Up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601292988","repostId":"1166348149","repostType":4,"repost":{"id":"1166348149","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638522212,"share":"https://www.laohu8.com/m/news/1166348149?lang=zh_CN&edition=full","pubTime":"2021-12-03 17:03","market":"us","language":"en","title":"Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1166348149","media":"Tiger Newspress","summary":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter comple","content":"<p>Grab stock rallied 7% in premarket trading&nbsp;after&nbsp;plunging&nbsp;20% on first day of trading.</p><p><blockquote>Grab股价在首日交易暴跌20%后，在盘前交易中上涨7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings&nbsp;Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p><p><blockquote>Grab Holdings Ltd.在完成了特殊目的收购公司迄今为止最富有的交易后。周四，即在美国交易的第一天，该股经历了最初的上涨，但随后暴跌至20%以上的跌幅。</blockquote></p><p> The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview&nbsp;on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p><p><blockquote>这家总部位于新加坡的公司开发了一款“超级应用”，在东南亚400多个城市提供叫车、送货和金融服务。Grab首席财务官Peter Oey周四在接受采访时表示，由于东南亚（尤其是越南）与COVID-19相关的停工，该公司在截至9月30日的第三季度经历了“最艰难的时期”。但他指出，尽管该公司正在关注新型冠状病毒变种奥密克戎的情况，但预计增长和复苏仍将持续。</blockquote></p><p> Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp.&nbsp;and SoftBank Group Corp.'s Vision Fund.</p><p><blockquote>Grab成立于2012年，其支持者包括滴滴出行、丰田汽车和软银集团的愿景基金。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-03 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab stock rallied 7% in premarket trading&nbsp;after&nbsp;plunging&nbsp;20% on first day of trading.</p><p><blockquote>Grab股价在首日交易暴跌20%后，在盘前交易中上涨7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings&nbsp;Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p><p><blockquote>Grab Holdings Ltd.在完成了特殊目的收购公司迄今为止最富有的交易后。周四，即在美国交易的第一天，该股经历了最初的上涨，但随后暴跌至20%以上的跌幅。</blockquote></p><p> The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview&nbsp;on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p><p><blockquote>这家总部位于新加坡的公司开发了一款“超级应用”，在东南亚400多个城市提供叫车、送货和金融服务。Grab首席财务官Peter Oey周四在接受采访时表示，由于东南亚（尤其是越南）与COVID-19相关的停工，该公司在截至9月30日的第三季度经历了“最艰难的时期”。但他指出，尽管该公司正在关注新型冠状病毒变种奥密克戎的情况，但预计增长和复苏仍将持续。</blockquote></p><p> Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp.&nbsp;and SoftBank Group Corp.'s Vision Fund.</p><p><blockquote>Grab成立于2012年，其支持者包括滴滴出行、丰田汽车和软银集团的愿景基金。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166348149","content_text":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter completing the richest deal yet for a special-purpose acquisition company,Grab Holdings Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.\nThe Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.\nBackers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp. and SoftBank Group Corp.'s Vision Fund.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":3907,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879637577,"gmtCreate":1636715008912,"gmtModify":1636715009013,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Liked","listText":"Liked","text":"Liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879637577","repostId":"1149394295","repostType":4,"repost":{"id":"1149394295","kind":"news","pubTimestamp":1636714672,"share":"https://www.laohu8.com/m/news/1149394295?lang=zh_CN&edition=full","pubTime":"2021-11-12 18:57","market":"us","language":"en","title":"Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149394295","media":"Reuters","summary":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar","content":"<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&amp;Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-12 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&amp;Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTCO":"Natura & Co Holding SA"},"source_url":"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149394295","content_text":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.\nNatura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.\nThe company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.\nIt reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.\nNatura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.\nOn the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.\nHe praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.\nMarques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.\nAccording to Marques, Natura has had a hard time raising prices as key markets deal with these issues.\n\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.","news_type":1,"symbols_score_info":{"NTCO":0.9}},"isVote":1,"tweetType":1,"viewCount":3266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447407,"gmtCreate":1636024166653,"gmtModify":1636024166821,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447407","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohu8.com/m/news/1101079537?lang=zh_CN&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernamRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&amp;D)以及销售、一般和行政(SG&amp;A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&amp;A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernamRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&amp;D)以及销售、一般和行政(SG&amp;A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&amp;A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859021205,"gmtCreate":1634641639710,"gmtModify":1634641747081,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859021205","repostId":"1111431743","repostType":4,"repost":{"id":"1111431743","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634637193,"share":"https://www.laohu8.com/m/news/1111431743?lang=zh_CN&edition=full","pubTime":"2021-10-19 17:53","market":"us","language":"en","title":"Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111431743","media":"Benzinga","summary":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo","content":"<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-10-19 17:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111431743","content_text":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.\nWhat Happened: The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.\nThe design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.\nWhy It Matters: The semiconductor foray replicates similar moves from rival computing players such as Huawei Technologies and Amazon.com Inc.\nAlibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.\nThe Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.\nPrice Action: Alibaba shares closed 0.68% lower at $166.82 a share on Monday.","news_type":1,"symbols_score_info":{"BABA":0.9,"09988":0.9}},"isVote":1,"tweetType":1,"viewCount":2738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826762189,"gmtCreate":1634055708286,"gmtModify":1634055782125,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826762189","repostId":"1188785088","repostType":4,"repost":{"id":"1188785088","kind":"news","pubTimestamp":1634052465,"share":"https://www.laohu8.com/m/news/1188785088?lang=zh_CN&edition=full","pubTime":"2021-10-12 23:27","market":"us","language":"en","title":"Tesla Stock: The Path To $2,500 By 2030<blockquote>特斯拉股票：到2030年将达到2,500美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188785088","media":"Seeking Alpha","summary":"Summary\n\nTesla experienced explosive gains last year.\nThis year, the stock has struggled, but the co","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Tesla experienced explosive gains last year.</li>  <li>This year, the stock has struggled, but the company is on the right track.</li>  <li>Better-than-anticipated production and deliveries data suggests the stock can push higher into year-end.</li>  <li>I suspect Tesla has more upside, and the stock could hit $2,500 in future years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/207deb1c8eb2af0f4c49abcb18226dd4\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Spencer Platt/Getty Images News</span></p><p><blockquote><ul><li>特斯拉去年经历了爆炸性的增长。</li><li>今年，该股表现不佳，但该公司正走在正确的轨道上。</li><li>好于预期的生产和交付数据表明该股可能会在年底前走高。</li><li>我怀疑特斯拉还有更大的上涨空间，该股未来几年可能会触及2,500美元。</li></ul><p class=\"t-img-caption\"><span>斯宾塞·普拉特/盖蒂图片社新闻</span></p></blockquote></p><p> I've been a Tesla(NASDAQ:TSLA)bull for a long time now. It's hard to believe, but the first time I purchased Tesla's stock was eight years ago when the share price was around a split-adjusted $30. Now, roughly 2,500% higher, I am still long Tesla and I think there is more upside in this stock. Tesla remains the leader in the ultra-lucrative EV space. The company arguably has the best products, powered by the most advanced technologies.</p><p><blockquote>我长期以来一直看好特斯拉（纳斯达克：TSLA）。很难相信，我第一次购买特斯拉的股票是在八年前，当时股价约为分拆调整后的30美元。现在，大约上涨了2,500%，我仍然做多特斯拉，我认为这只股票还有更大的上涨空间。特斯拉仍然是利润丰厚的电动汽车领域的领导者。该公司可以说拥有最好的产品，由最先进的技术驱动。</blockquote></p><p> Additionally, Tesla has a unique set of competitive advantages that the company utilizes to stay ahead of its competition year after year. Tesla just put up stellar delivery and production numbers, will likely surpass analysts' expectations this quarter, and the company has enormous revenue and EPS growth potential as we advance. While we will not see Tesla shares gain another 2,500% from here any time soon, the stock can probably hit $1,000 by year-end or early next year. Moreover, Tesla shares could climb substantially higher over the next several years as well.</p><p><blockquote>此外，特斯拉拥有一系列独特的竞争优势，该公司利用这些优势年复一年地在竞争中保持领先地位。特斯拉刚刚公布了出色的交付和生产数据，本季度可能会超出分析师的预期，随着我们的发展，该公司拥有巨大的收入和每股收益增长潜力。虽然我们不会看到特斯拉股价很快再上涨2,500%，但到年底或明年初，该股可能会触及1,000美元。此外，特斯拉股价在未来几年也可能大幅攀升。</blockquote></p><p> <b>Technical Setup</b></p><p><blockquote><b>技术设置</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dabe94c8ac775d6a4113df03ad66ffdb\" tg-width=\"640\" tg-height=\"676\" width=\"100%\" height=\"auto\"><span>Source: Stockcharts.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：Stockcharts.com</span></p></blockquote></p><p> Tesla had a stellar run-up in 2020 and into year-end last year. Then the stock experienced a significant correction of around 40% down to the $550 level. After this giant pullback, Tesla shares came back for a successful retest of the $550 level. Since then, the stock has been in a steady, concise, upward channel. The current move higher should continue until the bullish trend breaks. However, the bullish trend is robust and could power Tesla shares to $1,000 by the end of this year. Moreover, the company has numerous favorable fundamental factors to go along with the constructive technical setup right now.</p><p><blockquote>特斯拉在2020年和去年年底取得了出色的增长。随后该股经历了约40%的大幅回调，跌至550美元的水平。在这次大幅回调之后，特斯拉股价卷土重来，成功重新测试550美元水平。此后，该股一直处于稳定、简洁的上升通道中。目前的上涨应该会持续到看涨趋势被打破。然而，看涨趋势强劲，可能会推动特斯拉股价在今年年底前升至1,000美元。此外，该公司目前拥有许多有利的基本面因素来配合建设性的技术设置。</blockquote></p><p> <b>Competitive Edge</b></p><p><blockquote><b>竞争优势</b></blockquote></p><p> Tesla continues to enjoy a multifaceted competitive advantage relative to its peers. Its approach to marketing, sales, software development, battery production, supercharging, design, development, and production provides Tesla with a significant edge relative to its competitors. Tesla designs and delivers everything from scratch, and the company remains ever focused on staying ahead of the curve innovation-wise in the EV space. However, most traditional automakers are still mainly focused on ICE vehicles and are still pivoting towards EVs. The bottom line is that the EV market is continuously gaining share over the conventional ICE market, and Tesla is the clear leader when it comes to EVs.</p><p><blockquote>相对于同行，特斯拉继续享有多方面的竞争优势。其营销、销售、软件开发、电池生产、增压、设计、开发和生产方法使特斯拉相对于竞争对手具有显着优势。特斯拉从头开始设计和交付一切，该公司始终专注于在电动汽车领域的创新方面保持领先地位。然而，大多数传统汽车制造商仍然主要专注于内燃机汽车，并且仍在转向电动汽车。最重要的是，电动汽车市场正在不断获得传统内燃机市场的份额，而特斯拉在电动汽车方面显然是领导者。</blockquote></p><p> <b>Global EV Market Share First Half of 2021</b></p><p><blockquote><b>2021年上半年全球电动汽车市场份额</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/460efe2072a471a917fc24f40e742d6e\" tg-width=\"640\" tg-height=\"497\" width=\"100%\" height=\"auto\"><span>Source: statista.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：statista.com</span></p></blockquote></p><p> <b>Deliveries Surge</b></p><p><blockquote><b>交付量激增</b></blockquote></p><p> Tesla just announced another record deliveries quarter of&nbsp;241,300 vehiclesin Q3, a&nbsp;20% increase&nbsp;over the last quarter and a remarkable&nbsp;73% YoY surge. Tesla delivered a total of 9,275 Model S/X vehicles along with 232,025 mainstream Model 3/Y cars. Now, if we adjust for lease vehicles, we arrive at about 7,420 Model S/X vehicle sales and roughly 218,104 Model 3/Y vehicles sold in the third quarter.</p><p><blockquote>特斯拉刚刚宣布第三季度交付量再创新高，达到241,300辆，比上一季度增长20%，同比大幅增长73%。特斯拉总共交付了9,275辆Model S/X汽车以及232,025辆主流Model 3/Y汽车。现在，如果我们对租赁车辆进行调整，我们得出第三季度Model S/X汽车销量约为7,420辆，Model 3/Y汽车销量约为218,104辆。</blockquote></p><p> Last quarter (Q2 2021), Tesla sold (leases excluded) a total of about 187,163 vehicles for&nbsp;$9.874 billion. This sales image suggests that the average selling price (\"ASP\") across all vehicles was roughly $53K. Tesla sold approximately 1,550 Model S/X vehicles in Q2. Thus, if we approximate an ASP of $100,000 - $110,000 for Model S/X vehicle sales, we are left with about $52,000 for the Model 3/Y segment.</p><p><blockquote>上个季度（2021年第二季度），特斯拉总共售出（不包括租赁）约187,163辆汽车，价值98.74亿美元。这张销售图片表明，所有车辆的平均售价(“ASP”)约为5.3万美元。特斯拉在Q2销售了约1550辆Model S/X汽车。因此，如果我们估计Model S/X车辆销售的平均售价为100,000-110,000美元，那么Model 3/Y细分市场的平均售价约为52,000美元。</blockquote></p><p> Therefore, to get an approximate number for Tesla vehicle sales in Q3, we can use an ASP of $105,000 for the 7,420 Model S/X vehicles sold in the quarter, and we can use the $52,000 ASP for the 218,104 Model 3/Y cars delivered in Q3. This estimate gives us an approximate $800 million in Model S/X sales and $11.34 billion in Model 3/Y sales.</p><p><blockquote>因此，要获得第三季度特斯拉汽车销量的大致数字，我们可以对该季度售出的7,420辆Model S/X汽车使用105,000美元的ASP，对218,104辆Model 3/Y汽车使用52,000美元的ASP在第三季度交付。根据这一估计，Model S/X的销售额约为8亿美元，Model 3/Y的销售额约为113.4亿美元。</blockquote></p><p> <b>Q3 Earnings Outlook</b></p><p><blockquote><b>第三季度盈利展望</b></blockquote></p><p> <b>Analysts Estimates:</b></p><p><blockquote><b>分析师估计：</b></blockquote></p><p></p><p> Last quarter, Tesla delivered&nbsp;$1.45 in EPS, beating consensus analysts' forecasts by about $0.47 or 48%. The company announced revenues of $11.96 billion, beating estimates by $559.33 million simultaneously. Now for Q3, consensus estimates are for EPS of $1.47 and revenues of $13.49 billion. However, I think Tesla will beat these figures as well.</p><p><blockquote>上季度，特斯拉的每股收益为1.45美元，比分析师普遍预期高出约0.47美元，即48%。该公司宣布营收为119.6亿美元，同时超出预期5.5933亿美元。目前，第三季度的普遍预期是每股收益为1.47美元，营收为134.9亿美元。然而，我认为特斯拉也会超过这些数字。</blockquote></p><p> <b>My Estimates:</b></p><p><blockquote><b>我的估计：</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49202e7907ab71b56fdc7a9bd908431d\" tg-width=\"640\" tg-height=\"975\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p><p><blockquote><p class=\"t-img-caption\"><span>来源：作者材料</span></p></blockquote></p><p> Instead of the $13.49 billion revenues figure, I am looking for $14.74 billion in revenues, about a 9% increase over consensus expectations. Moreover, I think we can see about $1.85 in non-GAAP EPS out of Tesla in Q3, roughly 26% better than the current consensus figures imply. If Tesla makes good on its notably better-than-expected Q3 results, the stock will have a strong catalyst for a rally into year-end.</p><p><blockquote>我预计的收入不是134.9亿美元，而是147.4亿美元，比普遍预期增长约9%。此外，我认为我们可以看到特斯拉第三季度的非GAAP每股收益约为1.85美元，比当前共识数据高出约26%。如果特斯拉实现明显好于预期的第三季度业绩，该股将成为年底反弹的强大催化剂。</blockquote></p><p> <b>Bright Future Ahead for Tesla</b></p><p><blockquote><b>特斯拉前途光明</b></blockquote></p><p> Estimates are moving up for Tesla. There have been&nbsp;26 upward revisions&nbsp;relative to just one downward (FY2021) revision over the last 90 days. Still, estimates could continue to move higher.</p><p><blockquote>对特斯拉的估计正在上升。在过去90天内，有26次上调，而只有一次下调（2021财年）。尽管如此，预期可能会继续走高。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bda469abb83b22a2a4505ae8d0373158\" tg-width=\"640\" tg-height=\"276\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> First, I want to draw your attention to the number of beats in recent quarters. Sure, Tesla's earnings remain somewhat volatile, but it's difficult to deny the better-than-anticipated earnings growth of late. Consensus estimates were for $3.61 in EPS for the last four quarters. Yet, the company's actual EPS numbers came in at $3.94, an average beat of around 9% over consensus estimates. We already see estimates that are substantial increases on a YoY basis, but I think that results can continue to come in stronger than anticipated (by about 10-20%) as we advance.</p><p><blockquote>首先，我想提请您注意最近几个季度的节拍数量。当然，特斯拉的盈利仍然有些波动，但很难否认最近好于预期的盈利增长。市场普遍预期过去四个季度的每股收益为3.61美元。然而，该公司的实际每股收益为3.94美元，平均比市场普遍预期高出9%左右。我们已经看到了同比大幅增长的估计，但我认为随着我们的进展，结果可能会继续强于预期（约10-20%）。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8eb9918909984b4de589a4266c10f2a5\" tg-width=\"640\" tg-height=\"282\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3215da27370b6e97c23883ece163f6b\" tg-width=\"640\" tg-height=\"279\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> We see expectations for significant EPS and revenue gains in future years for Tesla. While the stock may seem relatively expensive right now, shares should become increasingly less costly as EPS surge in coming years.</p><p><blockquote>我们预计特斯拉未来几年的每股收益和收入将大幅增长。虽然该股目前看起来相对昂贵，但随着未来几年每股收益的飙升，该股的成本应该会越来越低。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4392b7b8eeb3a6fc412f6cd79fe9e44e\" tg-width=\"640\" tg-height=\"330\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> Here is what Tesla's EPS, P/E ratio, and share price could look like in future years.</p><p><blockquote>以下是特斯拉未来几年的每股收益、市盈率和股价。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b9e110af6b9747752c5a540bdb00c5a4\" tg-width=\"905\" tg-height=\"382\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p><p><blockquote><p class=\"t-img-caption\"><span>来源：作者材料</span></p></blockquote></p><p> <b>The Bottom Line</b></p><p><blockquote><b>底线</b></blockquote></p><p> Tesla's steady and robust EPS growth trend should continue, and I expect the company's share price could reach $2,500 or higher by the end of the decade. Now, some market participants could argue that these stock price projections are optimistic. However, I think that these projections may be relatively modest. First, the company could deliver higher EPS than I anticipate in future years, and second, Tesla's P/E ratio could remain elevated for longer.</p><p><blockquote>特斯拉稳定强劲的每股收益增长趋势应该会持续下去，我预计该公司的股价到本世纪末可能会达到2,500美元或更高。现在，一些市场参与者可能会认为这些股价预测是乐观的。然而，我认为这些预测可能相对温和。首先，该公司未来几年的每股收益可能会高于我的预期，其次，特斯拉的市盈率可能会在更长时间内保持较高水平。</blockquote></p><p> Due to Tesla's unique growth dynamic, the only company that can compare to Tesla is Amazon(NASDAQ:AMZN), in my view. Amazon's current valuation is what a more mature Tesla valuation could become. Incidentally, Amazon currently trades at about 58 times EPS, exactly where I have my 2029 Tesla P/E ratio pegged. Also, the projected stock price appreciation is only 220% from current levels, which is relatively modest if we consider the number of years.</p><p><blockquote>由于特斯拉独特的增长动力，在我看来，唯一可以与特斯拉相比的公司是亚马逊（纳斯达克：AMZN）。亚马逊目前的估值是更成熟的特斯拉估值可能达到的水平。顺便说一句，亚马逊目前的市盈率约为58倍，这正是我对2029年特斯拉市盈率的预期。此外，预计股价较当前水平仅上涨220%，如果考虑年数，这一涨幅相对较小。</blockquote></p><p> <b>Risks to Tesla's $2,500 Price Target</b></p><p><blockquote><b>特斯拉2,500美元目标价面临风险</b></blockquote></p><p> Of course, when you are talking about Tesla, there are risks to consider. While I estimate that the company can earn close to $50 per share by 2030, the company is very far from such figures right now. Therefore, there is the risk that Tesla will not illustrate the kind of earnings growth I envision. A slowdown in demand, increased competition, supply issues, decreased growth, and other variables are all risks we should consider before betting on Tesla to increase EPS nearly tenfold by 2030. Serious concerns could cause Tesla's valuation to lose altitude, and the company's share price could even head in reverse if any serious issues should arise. Therefore, I believe one should consider the risks carefully before committing any capital to a Tesla investment.</p><p><blockquote>当然，当你谈论特斯拉时，有风险需要考虑。虽然我估计到2030年该公司每股收益可接近50美元，但该公司目前距离这样的数字还很远。因此，特斯拉存在无法实现我所设想的盈利增长的风险。需求放缓、竞争加剧、供应问题、增长下降和其他变量都是我们在押注特斯拉到2030年每股收益增长近十倍之前应该考虑的风险。严重的担忧可能会导致特斯拉的估值下降，如果出现任何严重问题，该公司的股价甚至可能出现逆转。因此，我认为在投入任何资金进行特斯拉投资之前，应该仔细考虑风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock: The Path To $2,500 By 2030<blockquote>特斯拉股票：到2030年将达到2,500美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock: The Path To $2,500 By 2030<blockquote>特斯拉股票：到2030年将达到2,500美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-10-12 23:27</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Tesla experienced explosive gains last year.</li>  <li>This year, the stock has struggled, but the company is on the right track.</li>  <li>Better-than-anticipated production and deliveries data suggests the stock can push higher into year-end.</li>  <li>I suspect Tesla has more upside, and the stock could hit $2,500 in future years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/207deb1c8eb2af0f4c49abcb18226dd4\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Spencer Platt/Getty Images News</span></p><p><blockquote><ul><li>特斯拉去年经历了爆炸性的增长。</li><li>今年，该股表现不佳，但该公司正走在正确的轨道上。</li><li>好于预期的生产和交付数据表明该股可能会在年底前走高。</li><li>我怀疑特斯拉还有更大的上涨空间，该股未来几年可能会触及2,500美元。</li></ul><p class=\"t-img-caption\"><span>斯宾塞·普拉特/盖蒂图片社新闻</span></p></blockquote></p><p> I've been a Tesla(NASDAQ:TSLA)bull for a long time now. It's hard to believe, but the first time I purchased Tesla's stock was eight years ago when the share price was around a split-adjusted $30. Now, roughly 2,500% higher, I am still long Tesla and I think there is more upside in this stock. Tesla remains the leader in the ultra-lucrative EV space. The company arguably has the best products, powered by the most advanced technologies.</p><p><blockquote>我长期以来一直看好特斯拉（纳斯达克：TSLA）。很难相信，我第一次购买特斯拉的股票是在八年前，当时股价约为分拆调整后的30美元。现在，大约上涨了2,500%，我仍然做多特斯拉，我认为这只股票还有更大的上涨空间。特斯拉仍然是利润丰厚的电动汽车领域的领导者。该公司可以说拥有最好的产品，由最先进的技术驱动。</blockquote></p><p> Additionally, Tesla has a unique set of competitive advantages that the company utilizes to stay ahead of its competition year after year. Tesla just put up stellar delivery and production numbers, will likely surpass analysts' expectations this quarter, and the company has enormous revenue and EPS growth potential as we advance. While we will not see Tesla shares gain another 2,500% from here any time soon, the stock can probably hit $1,000 by year-end or early next year. Moreover, Tesla shares could climb substantially higher over the next several years as well.</p><p><blockquote>此外，特斯拉拥有一系列独特的竞争优势，该公司利用这些优势年复一年地在竞争中保持领先地位。特斯拉刚刚公布了出色的交付和生产数据，本季度可能会超出分析师的预期，随着我们的发展，该公司拥有巨大的收入和每股收益增长潜力。虽然我们不会看到特斯拉股价很快再上涨2,500%，但到年底或明年初，该股可能会触及1,000美元。此外，特斯拉股价在未来几年也可能大幅攀升。</blockquote></p><p> <b>Technical Setup</b></p><p><blockquote><b>技术设置</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dabe94c8ac775d6a4113df03ad66ffdb\" tg-width=\"640\" tg-height=\"676\" width=\"100%\" height=\"auto\"><span>Source: Stockcharts.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：Stockcharts.com</span></p></blockquote></p><p> Tesla had a stellar run-up in 2020 and into year-end last year. Then the stock experienced a significant correction of around 40% down to the $550 level. After this giant pullback, Tesla shares came back for a successful retest of the $550 level. Since then, the stock has been in a steady, concise, upward channel. The current move higher should continue until the bullish trend breaks. However, the bullish trend is robust and could power Tesla shares to $1,000 by the end of this year. Moreover, the company has numerous favorable fundamental factors to go along with the constructive technical setup right now.</p><p><blockquote>特斯拉在2020年和去年年底取得了出色的增长。随后该股经历了约40%的大幅回调，跌至550美元的水平。在这次大幅回调之后，特斯拉股价卷土重来，成功重新测试550美元水平。此后，该股一直处于稳定、简洁的上升通道中。目前的上涨应该会持续到看涨趋势被打破。然而，看涨趋势强劲，可能会推动特斯拉股价在今年年底前升至1,000美元。此外，该公司目前拥有许多有利的基本面因素来配合建设性的技术设置。</blockquote></p><p> <b>Competitive Edge</b></p><p><blockquote><b>竞争优势</b></blockquote></p><p> Tesla continues to enjoy a multifaceted competitive advantage relative to its peers. Its approach to marketing, sales, software development, battery production, supercharging, design, development, and production provides Tesla with a significant edge relative to its competitors. Tesla designs and delivers everything from scratch, and the company remains ever focused on staying ahead of the curve innovation-wise in the EV space. However, most traditional automakers are still mainly focused on ICE vehicles and are still pivoting towards EVs. The bottom line is that the EV market is continuously gaining share over the conventional ICE market, and Tesla is the clear leader when it comes to EVs.</p><p><blockquote>相对于同行，特斯拉继续享有多方面的竞争优势。其营销、销售、软件开发、电池生产、增压、设计、开发和生产方法使特斯拉相对于竞争对手具有显着优势。特斯拉从头开始设计和交付一切，该公司始终专注于在电动汽车领域的创新方面保持领先地位。然而，大多数传统汽车制造商仍然主要专注于内燃机汽车，并且仍在转向电动汽车。最重要的是，电动汽车市场正在不断获得传统内燃机市场的份额，而特斯拉在电动汽车方面显然是领导者。</blockquote></p><p> <b>Global EV Market Share First Half of 2021</b></p><p><blockquote><b>2021年上半年全球电动汽车市场份额</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/460efe2072a471a917fc24f40e742d6e\" tg-width=\"640\" tg-height=\"497\" width=\"100%\" height=\"auto\"><span>Source: statista.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：statista.com</span></p></blockquote></p><p> <b>Deliveries Surge</b></p><p><blockquote><b>交付量激增</b></blockquote></p><p> Tesla just announced another record deliveries quarter of&nbsp;241,300 vehiclesin Q3, a&nbsp;20% increase&nbsp;over the last quarter and a remarkable&nbsp;73% YoY surge. Tesla delivered a total of 9,275 Model S/X vehicles along with 232,025 mainstream Model 3/Y cars. Now, if we adjust for lease vehicles, we arrive at about 7,420 Model S/X vehicle sales and roughly 218,104 Model 3/Y vehicles sold in the third quarter.</p><p><blockquote>特斯拉刚刚宣布第三季度交付量再创新高，达到241,300辆，比上一季度增长20%，同比大幅增长73%。特斯拉总共交付了9,275辆Model S/X汽车以及232,025辆主流Model 3/Y汽车。现在，如果我们对租赁车辆进行调整，我们得出第三季度Model S/X汽车销量约为7,420辆，Model 3/Y汽车销量约为218,104辆。</blockquote></p><p> Last quarter (Q2 2021), Tesla sold (leases excluded) a total of about 187,163 vehicles for&nbsp;$9.874 billion. This sales image suggests that the average selling price (\"ASP\") across all vehicles was roughly $53K. Tesla sold approximately 1,550 Model S/X vehicles in Q2. Thus, if we approximate an ASP of $100,000 - $110,000 for Model S/X vehicle sales, we are left with about $52,000 for the Model 3/Y segment.</p><p><blockquote>上个季度（2021年第二季度），特斯拉总共售出（不包括租赁）约187,163辆汽车，价值98.74亿美元。这张销售图片表明，所有车辆的平均售价(“ASP”)约为5.3万美元。特斯拉在Q2销售了约1550辆Model S/X汽车。因此，如果我们估计Model S/X车辆销售的平均售价为100,000-110,000美元，那么Model 3/Y细分市场的平均售价约为52,000美元。</blockquote></p><p> Therefore, to get an approximate number for Tesla vehicle sales in Q3, we can use an ASP of $105,000 for the 7,420 Model S/X vehicles sold in the quarter, and we can use the $52,000 ASP for the 218,104 Model 3/Y cars delivered in Q3. This estimate gives us an approximate $800 million in Model S/X sales and $11.34 billion in Model 3/Y sales.</p><p><blockquote>因此，要获得第三季度特斯拉汽车销量的大致数字，我们可以对该季度售出的7,420辆Model S/X汽车使用105,000美元的ASP，对218,104辆Model 3/Y汽车使用52,000美元的ASP在第三季度交付。根据这一估计，Model S/X的销售额约为8亿美元，Model 3/Y的销售额约为113.4亿美元。</blockquote></p><p> <b>Q3 Earnings Outlook</b></p><p><blockquote><b>第三季度盈利展望</b></blockquote></p><p> <b>Analysts Estimates:</b></p><p><blockquote><b>分析师估计：</b></blockquote></p><p></p><p> Last quarter, Tesla delivered&nbsp;$1.45 in EPS, beating consensus analysts' forecasts by about $0.47 or 48%. The company announced revenues of $11.96 billion, beating estimates by $559.33 million simultaneously. Now for Q3, consensus estimates are for EPS of $1.47 and revenues of $13.49 billion. However, I think Tesla will beat these figures as well.</p><p><blockquote>上季度，特斯拉的每股收益为1.45美元，比分析师普遍预期高出约0.47美元，即48%。该公司宣布营收为119.6亿美元，同时超出预期5.5933亿美元。目前，第三季度的普遍预期是每股收益为1.47美元，营收为134.9亿美元。然而，我认为特斯拉也会超过这些数字。</blockquote></p><p> <b>My Estimates:</b></p><p><blockquote><b>我的估计：</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/49202e7907ab71b56fdc7a9bd908431d\" tg-width=\"640\" tg-height=\"975\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p><p><blockquote><p class=\"t-img-caption\"><span>来源：作者材料</span></p></blockquote></p><p> Instead of the $13.49 billion revenues figure, I am looking for $14.74 billion in revenues, about a 9% increase over consensus expectations. Moreover, I think we can see about $1.85 in non-GAAP EPS out of Tesla in Q3, roughly 26% better than the current consensus figures imply. If Tesla makes good on its notably better-than-expected Q3 results, the stock will have a strong catalyst for a rally into year-end.</p><p><blockquote>我预计的收入不是134.9亿美元，而是147.4亿美元，比普遍预期增长约9%。此外，我认为我们可以看到特斯拉第三季度的非GAAP每股收益约为1.85美元，比当前共识数据高出约26%。如果特斯拉实现明显好于预期的第三季度业绩，该股将成为年底反弹的强大催化剂。</blockquote></p><p> <b>Bright Future Ahead for Tesla</b></p><p><blockquote><b>特斯拉前途光明</b></blockquote></p><p> Estimates are moving up for Tesla. There have been&nbsp;26 upward revisions&nbsp;relative to just one downward (FY2021) revision over the last 90 days. Still, estimates could continue to move higher.</p><p><blockquote>对特斯拉的估计正在上升。在过去90天内，有26次上调，而只有一次下调（2021财年）。尽管如此，预期可能会继续走高。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bda469abb83b22a2a4505ae8d0373158\" tg-width=\"640\" tg-height=\"276\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> First, I want to draw your attention to the number of beats in recent quarters. Sure, Tesla's earnings remain somewhat volatile, but it's difficult to deny the better-than-anticipated earnings growth of late. Consensus estimates were for $3.61 in EPS for the last four quarters. Yet, the company's actual EPS numbers came in at $3.94, an average beat of around 9% over consensus estimates. We already see estimates that are substantial increases on a YoY basis, but I think that results can continue to come in stronger than anticipated (by about 10-20%) as we advance.</p><p><blockquote>首先，我想提请您注意最近几个季度的节拍数量。当然，特斯拉的盈利仍然有些波动，但很难否认最近好于预期的盈利增长。市场普遍预期过去四个季度的每股收益为3.61美元。然而，该公司的实际每股收益为3.94美元，平均比市场普遍预期高出9%左右。我们已经看到了同比大幅增长的估计，但我认为随着我们的进展，结果可能会继续强于预期（约10-20%）。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8eb9918909984b4de589a4266c10f2a5\" tg-width=\"640\" tg-height=\"282\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3215da27370b6e97c23883ece163f6b\" tg-width=\"640\" tg-height=\"279\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> We see expectations for significant EPS and revenue gains in future years for Tesla. While the stock may seem relatively expensive right now, shares should become increasingly less costly as EPS surge in coming years.</p><p><blockquote>我们预计特斯拉未来几年的每股收益和收入将大幅增长。虽然该股目前看起来相对昂贵，但随着未来几年每股收益的飙升，该股的成本应该会越来越低。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4392b7b8eeb3a6fc412f6cd79fe9e44e\" tg-width=\"640\" tg-height=\"330\" width=\"100%\" height=\"auto\"><span>Source: seekingalpha.com</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：seekingalpha.com</span></p></blockquote></p><p> Here is what Tesla's EPS, P/E ratio, and share price could look like in future years.</p><p><blockquote>以下是特斯拉未来几年的每股收益、市盈率和股价。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b9e110af6b9747752c5a540bdb00c5a4\" tg-width=\"905\" tg-height=\"382\" width=\"100%\" height=\"auto\"><span>Source: Author's Material</span></p><p><blockquote><p class=\"t-img-caption\"><span>来源：作者材料</span></p></blockquote></p><p> <b>The Bottom Line</b></p><p><blockquote><b>底线</b></blockquote></p><p> Tesla's steady and robust EPS growth trend should continue, and I expect the company's share price could reach $2,500 or higher by the end of the decade. Now, some market participants could argue that these stock price projections are optimistic. However, I think that these projections may be relatively modest. First, the company could deliver higher EPS than I anticipate in future years, and second, Tesla's P/E ratio could remain elevated for longer.</p><p><blockquote>特斯拉稳定强劲的每股收益增长趋势应该会持续下去，我预计该公司的股价到本世纪末可能会达到2,500美元或更高。现在，一些市场参与者可能会认为这些股价预测是乐观的。然而，我认为这些预测可能相对温和。首先，该公司未来几年的每股收益可能会高于我的预期，其次，特斯拉的市盈率可能会在更长时间内保持较高水平。</blockquote></p><p> Due to Tesla's unique growth dynamic, the only company that can compare to Tesla is Amazon(NASDAQ:AMZN), in my view. Amazon's current valuation is what a more mature Tesla valuation could become. Incidentally, Amazon currently trades at about 58 times EPS, exactly where I have my 2029 Tesla P/E ratio pegged. Also, the projected stock price appreciation is only 220% from current levels, which is relatively modest if we consider the number of years.</p><p><blockquote>由于特斯拉独特的增长动力，在我看来，唯一可以与特斯拉相比的公司是亚马逊（纳斯达克：AMZN）。亚马逊目前的估值是更成熟的特斯拉估值可能达到的水平。顺便说一句，亚马逊目前的市盈率约为58倍，这正是我对2029年特斯拉市盈率的预期。此外，预计股价较当前水平仅上涨220%，如果考虑年数，这一涨幅相对较小。</blockquote></p><p> <b>Risks to Tesla's $2,500 Price Target</b></p><p><blockquote><b>特斯拉2,500美元目标价面临风险</b></blockquote></p><p> Of course, when you are talking about Tesla, there are risks to consider. While I estimate that the company can earn close to $50 per share by 2030, the company is very far from such figures right now. Therefore, there is the risk that Tesla will not illustrate the kind of earnings growth I envision. A slowdown in demand, increased competition, supply issues, decreased growth, and other variables are all risks we should consider before betting on Tesla to increase EPS nearly tenfold by 2030. Serious concerns could cause Tesla's valuation to lose altitude, and the company's share price could even head in reverse if any serious issues should arise. Therefore, I believe one should consider the risks carefully before committing any capital to a Tesla investment.</p><p><blockquote>当然，当你谈论特斯拉时，有风险需要考虑。虽然我估计到2030年该公司每股收益可接近50美元，但该公司目前距离这样的数字还很远。因此，特斯拉存在无法实现我所设想的盈利增长的风险。需求放缓、竞争加剧、供应问题、增长下降和其他变量都是我们在押注特斯拉到2030年每股收益增长近十倍之前应该考虑的风险。严重的担忧可能会导致特斯拉的估值下降，如果出现任何严重问题，该公司的股价甚至可能出现逆转。因此，我认为在投入任何资金进行特斯拉投资之前，应该仔细考虑风险。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4459378-tesla-path-to-2500-by-2030\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://seekingalpha.com/article/4459378-tesla-path-to-2500-by-2030","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188785088","content_text":"Summary\n\nTesla experienced explosive gains last year.\nThis year, the stock has struggled, but the company is on the right track.\nBetter-than-anticipated production and deliveries data suggests the stock can push higher into year-end.\nI suspect Tesla has more upside, and the stock could hit $2,500 in future years.\n\nSpencer Platt/Getty Images News\nI've been a Tesla(NASDAQ:TSLA)bull for a long time now. It's hard to believe, but the first time I purchased Tesla's stock was eight years ago when the share price was around a split-adjusted $30. Now, roughly 2,500% higher, I am still long Tesla and I think there is more upside in this stock. Tesla remains the leader in the ultra-lucrative EV space. The company arguably has the best products, powered by the most advanced technologies.\nAdditionally, Tesla has a unique set of competitive advantages that the company utilizes to stay ahead of its competition year after year. Tesla just put up stellar delivery and production numbers, will likely surpass analysts' expectations this quarter, and the company has enormous revenue and EPS growth potential as we advance. While we will not see Tesla shares gain another 2,500% from here any time soon, the stock can probably hit $1,000 by year-end or early next year. Moreover, Tesla shares could climb substantially higher over the next several years as well.\nTechnical Setup\nSource: Stockcharts.com\nTesla had a stellar run-up in 2020 and into year-end last year. Then the stock experienced a significant correction of around 40% down to the $550 level. After this giant pullback, Tesla shares came back for a successful retest of the $550 level. Since then, the stock has been in a steady, concise, upward channel. The current move higher should continue until the bullish trend breaks. However, the bullish trend is robust and could power Tesla shares to $1,000 by the end of this year. Moreover, the company has numerous favorable fundamental factors to go along with the constructive technical setup right now.\nCompetitive Edge\nTesla continues to enjoy a multifaceted competitive advantage relative to its peers. Its approach to marketing, sales, software development, battery production, supercharging, design, development, and production provides Tesla with a significant edge relative to its competitors. Tesla designs and delivers everything from scratch, and the company remains ever focused on staying ahead of the curve innovation-wise in the EV space. However, most traditional automakers are still mainly focused on ICE vehicles and are still pivoting towards EVs. The bottom line is that the EV market is continuously gaining share over the conventional ICE market, and Tesla is the clear leader when it comes to EVs.\nGlobal EV Market Share First Half of 2021\nSource: statista.com\nDeliveries Surge\nTesla just announced another record deliveries quarter of 241,300 vehiclesin Q3, a 20% increase over the last quarter and a remarkable 73% YoY surge. Tesla delivered a total of 9,275 Model S/X vehicles along with 232,025 mainstream Model 3/Y cars. Now, if we adjust for lease vehicles, we arrive at about 7,420 Model S/X vehicle sales and roughly 218,104 Model 3/Y vehicles sold in the third quarter.\nLast quarter (Q2 2021), Tesla sold (leases excluded) a total of about 187,163 vehicles for $9.874 billion. This sales image suggests that the average selling price (\"ASP\") across all vehicles was roughly $53K. Tesla sold approximately 1,550 Model S/X vehicles in Q2. Thus, if we approximate an ASP of $100,000 - $110,000 for Model S/X vehicle sales, we are left with about $52,000 for the Model 3/Y segment.\nTherefore, to get an approximate number for Tesla vehicle sales in Q3, we can use an ASP of $105,000 for the 7,420 Model S/X vehicles sold in the quarter, and we can use the $52,000 ASP for the 218,104 Model 3/Y cars delivered in Q3. This estimate gives us an approximate $800 million in Model S/X sales and $11.34 billion in Model 3/Y sales.\nQ3 Earnings Outlook\nAnalysts Estimates:\nLast quarter, Tesla delivered $1.45 in EPS, beating consensus analysts' forecasts by about $0.47 or 48%. The company announced revenues of $11.96 billion, beating estimates by $559.33 million simultaneously. Now for Q3, consensus estimates are for EPS of $1.47 and revenues of $13.49 billion. However, I think Tesla will beat these figures as well.\nMy Estimates:\nSource: Author's Material\nInstead of the $13.49 billion revenues figure, I am looking for $14.74 billion in revenues, about a 9% increase over consensus expectations. Moreover, I think we can see about $1.85 in non-GAAP EPS out of Tesla in Q3, roughly 26% better than the current consensus figures imply. If Tesla makes good on its notably better-than-expected Q3 results, the stock will have a strong catalyst for a rally into year-end.\nBright Future Ahead for Tesla\nEstimates are moving up for Tesla. There have been 26 upward revisions relative to just one downward (FY2021) revision over the last 90 days. Still, estimates could continue to move higher.\nSource: seekingalpha.com\nFirst, I want to draw your attention to the number of beats in recent quarters. Sure, Tesla's earnings remain somewhat volatile, but it's difficult to deny the better-than-anticipated earnings growth of late. Consensus estimates were for $3.61 in EPS for the last four quarters. Yet, the company's actual EPS numbers came in at $3.94, an average beat of around 9% over consensus estimates. We already see estimates that are substantial increases on a YoY basis, but I think that results can continue to come in stronger than anticipated (by about 10-20%) as we advance.\nSource: seekingalpha.com\nSource: seekingalpha.com\nWe see expectations for significant EPS and revenue gains in future years for Tesla. While the stock may seem relatively expensive right now, shares should become increasingly less costly as EPS surge in coming years.\nSource: seekingalpha.com\nHere is what Tesla's EPS, P/E ratio, and share price could look like in future years.\nSource: Author's Material\nThe Bottom Line\nTesla's steady and robust EPS growth trend should continue, and I expect the company's share price could reach $2,500 or higher by the end of the decade. Now, some market participants could argue that these stock price projections are optimistic. However, I think that these projections may be relatively modest. First, the company could deliver higher EPS than I anticipate in future years, and second, Tesla's P/E ratio could remain elevated for longer.\nDue to Tesla's unique growth dynamic, the only company that can compare to Tesla is Amazon(NASDAQ:AMZN), in my view. Amazon's current valuation is what a more mature Tesla valuation could become. Incidentally, Amazon currently trades at about 58 times EPS, exactly where I have my 2029 Tesla P/E ratio pegged. Also, the projected stock price appreciation is only 220% from current levels, which is relatively modest if we consider the number of years.\nRisks to Tesla's $2,500 Price Target\nOf course, when you are talking about Tesla, there are risks to consider. While I estimate that the company can earn close to $50 per share by 2030, the company is very far from such figures right now. Therefore, there is the risk that Tesla will not illustrate the kind of earnings growth I envision. A slowdown in demand, increased competition, supply issues, decreased growth, and other variables are all risks we should consider before betting on Tesla to increase EPS nearly tenfold by 2030. Serious concerns could cause Tesla's valuation to lose altitude, and the company's share price could even head in reverse if any serious issues should arise. Therefore, I believe one should consider the risks carefully before committing any capital to a Tesla investment.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828779586,"gmtCreate":1633952916663,"gmtModify":1633952916663,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828779586","repostId":"2174064969","repostType":4,"isVote":1,"tweetType":1,"viewCount":3078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862950901,"gmtCreate":1632832381619,"gmtModify":1632832381719,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862950901","repostId":"2170670597","repostType":4,"isVote":1,"tweetType":1,"viewCount":3714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866605070,"gmtCreate":1632757990190,"gmtModify":1632798029312,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866605070","repostId":"2170462612","repostType":4,"isVote":1,"tweetType":1,"viewCount":2778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869568971,"gmtCreate":1632305103093,"gmtModify":1632801378740,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/869568971","repostId":"2169569506","repostType":4,"isVote":1,"tweetType":1,"viewCount":494,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860484940,"gmtCreate":1632198783280,"gmtModify":1632802111990,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860484940","repostId":"1137903223","repostType":4,"isVote":1,"tweetType":1,"viewCount":647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815859644,"gmtCreate":1630668421188,"gmtModify":1632467838648,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"WOW 🥺","listText":"WOW 🥺","text":"WOW 🥺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815859644","repostId":"2164288879","repostType":4,"isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810201389,"gmtCreate":1629977438641,"gmtModify":1633681075879,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/810201389","repostId":"1171909968","repostType":4,"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891182524,"gmtCreate":1628349184668,"gmtModify":1633751515667,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/891182524","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899971972,"gmtCreate":1628155634196,"gmtModify":1633753094090,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899971972","repostId":"1129515398","repostType":4,"repost":{"id":"1129515398","kind":"news","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=zh_CN&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<p>  Investors could soon have 200 million reasons to celebrate.  <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p><p><blockquote>投资者很快就会有2亿个理由庆祝。<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>继昨天飙升18%后，盘前交易中股价上涨超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p><p><blockquote>本公司之股份<b>Novavax</b>在这家生物技术公司达成向欧盟供应多达2亿剂冠状病毒候选疫苗的协议后，周三股价飙升18.7%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p><p><blockquote>如果Novavax的疫苗获得监管批准，欧盟委员会（EC）将购买多达1亿剂疫苗。该协议还赋予欧盟委员会到2023年额外购买1亿剂疫苗的选择权。</blockquote></p><p> Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p><p><blockquote>Novavax希望在第三季度完成其药物向欧洲药品管理局的滚动提交。Novavax首席执行官斯坦利·埃尔克(Stanley Erck)在一份新闻稿中表示：“我们试验的临床数据显示，针对令人担忧的变种和感兴趣的变种具有强大的功效，我们相信我们的候选疫苗将在帮助控制欧盟和世界其他地区的疫情方面发挥关键作用。”</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p><p><blockquote>Novavax在英国的一项3期临床试验中显示出针对COVID-19的总体疗效为89.7%。在该研究的大约15,000名参与者中，该药物的耐受性也普遍良好。卫生官员表示，在病例数以惊人的速度增加之际，该疫苗可能有助于减缓COVID-19的传播。</blockquote></p><p> \"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p><p><blockquote>欧盟委员会主席乌尔苏拉·冯德莱恩表示：“随着新的冠状病毒变种在欧洲和世界各地传播，与一家已经成功测试其针对这些变种的疫苗的公司签订的这份新合同是保护我们人口的额外保障。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-08-05 16:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  Investors could soon have 200 million reasons to celebrate.  <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p><p><blockquote>投资者很快就会有2亿个理由庆祝。<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>继昨天飙升18%后，盘前交易中股价上涨超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p><p><blockquote>本公司之股份<b>Novavax</b>在这家生物技术公司达成向欧盟供应多达2亿剂冠状病毒候选疫苗的协议后，周三股价飙升18.7%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p><p><blockquote>如果Novavax的疫苗获得监管批准，欧盟委员会（EC）将购买多达1亿剂疫苗。该协议还赋予欧盟委员会到2023年额外购买1亿剂疫苗的选择权。</blockquote></p><p> Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p><p><blockquote>Novavax希望在第三季度完成其药物向欧洲药品管理局的滚动提交。Novavax首席执行官斯坦利·埃尔克(Stanley Erck)在一份新闻稿中表示：“我们试验的临床数据显示，针对令人担忧的变种和感兴趣的变种具有强大的功效，我们相信我们的候选疫苗将在帮助控制欧盟和世界其他地区的疫情方面发挥关键作用。”</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p><p><blockquote>Novavax在英国的一项3期临床试验中显示出针对COVID-19的总体疗效为89.7%。在该研究的大约15,000名参与者中，该药物的耐受性也普遍良好。卫生官员表示，在病例数以惊人的速度增加之际，该疫苗可能有助于减缓COVID-19的传播。</blockquote></p><p> \"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p><p><blockquote>欧盟委员会主席乌尔苏拉·冯德莱恩表示：“随着新的冠状病毒变种在欧洲和世界各地传播，与一家已经成功测试其针对这些变种的疫苗的公司签订的这份新合同是保护我们人口的额外保障。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806132514,"gmtCreate":1627639750838,"gmtModify":1633757542718,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806132514","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://www.laohu8.com/m/news/1135561812?lang=zh_CN&edition=full","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>AMD's margin gains are driven by growing strength in end markets.</li>  <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>  <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>  <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p><p><blockquote><ul><li>AMD的利润率增长是由终端市场实力的增强推动的。</li><li>AMD将2021财年的收入指引上调了$1.0 B，毛利率接近50%。</li><li>即使增长放缓，这家半导体公司明年的自由现金流也可能达到$6.0 B。</li><li>AMD的美元销售额增长比Nvidia便宜，而且AMD的增长速度甚至可能更快。</li></ul><p class=\"t-img-caption\"><span>Jay_Zynism/iStock来自Getty Images</span></p></blockquote></p><p> AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p><p><blockquote>AMD(AMD)昨天引起了轰动，此前这家半导体公司公布的增长和利润率甚至好于预期。AMD的收入加速和毛利率强劲扩张为该股的上涨提供了强有力的理由。</blockquote></p><p> <b>Why AMD is worth $120</b></p><p><blockquote><b>为什么AMD值120美元</b></blockquote></p><p> Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p><p><blockquote>在我深入了解AMD的最新业绩之前，让我们快速回顾一下该公司上季度的指引。对于21年第二季度，AMD预计收入至少为$3.5 B，“高案例”指导意味着收入环比增长7%，毛利率为47%。</blockquote></p><p> I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p><p><blockquote>我预计AMD的收入将达到指导上限（$3.7 B），最低自由现金流为8.95亿美元（环比增长8%），自由现金流利润率为24%。鉴于价格较高的锐龙台式机和笔记本处理器和GPU的销售加速，以及终端市场广泛实力推动的平均售价/ASP上升，我预计AMD将超出自己的利润率指导，并报告毛利率21年第二季度为48%。我还预测，由于CPU和GPU平均售价的强劲，AMD的毛利率指引将会更新。我在《AMD：迈向50亿美元的年度自由现金流》中详细阐述了对AMD 21年第二季度收益的预测。</blockquote></p><p> Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p><p><blockquote>谈到AMD的实际业绩，这家半导体公司再次证明了它正在全力以赴。AMD 21年第二季度的收入为38.5亿美元，比指导上限高出1.5亿美元，环比增长12%，图形/计算和企业市场的收入势头仍在继续。由于客户端和图形处理器销售额的增加以及平均售价的提高，图形/计算收入环比增长7%，达到22.5亿美元。企业业务已成为AMD近几个季度销售增长的驱动力，21年第二季度收入为$1.6 B，环比增长19%。继AMD在21年第一季度录得5%的季度收入增长后，企业收入在21年第二季度继续加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p><p><blockquote>然而，AMD 21年第二季度收益中最有趣的启示是毛利率的趋势。AMD的毛利率跃升4个百分点至48%，比指导值高出1个百分点，原因是价格较高的锐龙处理器（移动和桌面）和镭龙显卡的更好组合。21年第二季度毛利率的上升标志着AMD利润率连续第三个季度扩张，我认为AMD还没有看到这一趋势的结束。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> Turning to cash flow.</p><p><blockquote>转向现金流。</blockquote></p><p> AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p><p><blockquote>AMD报告的经营活动现金流为9.52亿美元，自由现金流为8.88亿美元，比我的预期低700万美元，但仍是一年前的近六倍。随着AMD在计算/图形和企业终端市场继续看到强劲的收入增长，我相信AMD可以在明年年底前将其自由现金流利润率提高到30%。AMD将2021财年的收入指引（稍后讨论）提高了$1.0 B，这意味着我也刷新了今年和明年的自由现金流预期。</blockquote></p><p> AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p><p><blockquote>AMD预计今年的收入为$15.6 B。假设稳定的自由现金流利润率为23-24%，AMD预计自由现金流为$3.6 B至$3.7 B。明年的收入预期尚未更新，但AMD在2022财年的收入应至少为$20B（假设同比增长25%），这意味着明年的自由现金流为$4.6 B至$4.8 B……而这些预期并未考虑AMD第三代EPYC Milan驱动的服务器处理器和价格更高的GPU提高AMD自由现金流利润率的可能性。明年30%的自由现金流利润率意味着自由现金流为$6.0 B。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p><p><blockquote><table><tbody><tr></tr></tbody></table>AMD预计收入为41亿美元+/-1亿美元，该公司更新了2021财年收入和毛利率指引（如预期）。AMD目前预计2021财年收入增长60%（之前为50%），毛利率为48%（之前为47%）。假设收入增长60%，AMD目前预计全年收入为$15.6 B（之前为$14.6 B），因此AMD的新指导评级为$1.0 B的额外收入，这些收入迄今为止尚未计入AMD的市值。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p><p><blockquote>AMD较高的毛利率和销售指引为该公司股票升值创造了强大的力量。由于AMD股价最近下跌以及收入增加了$1.0 B，AMD的美元销售额增长在盈利后变得更加便宜。AMD的美元销售额增长低于Nvidia，而且AMD的增长速度可能更快：AMD的收入指导评级为同比增长60%，对Nvidia的预测意味着2021财年“仅”同比增长49%。AMD的市值与市盈率为42.5，对于一家收入增长60%、毛利率接近50%的公司来说，这是很低的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p><p><blockquote><table><tbody><tr></tr></tbody></table>基于2022财年每股收益17.29美元，Nvidia的市盈率为44.5。如果AMD的盈利增长（2022财年每股收益为2.71美元）与Nvidia的估值相同，AMD的公平价格将为120美元（2.71美元x 44.5盈利乘数系数），表明上涨空间为17%。</blockquote></p><p> <b>Challenges to my price target</b></p><p><blockquote><b>我的价格目标面临的挑战</b></blockquote></p><p> The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p><p><blockquote>AMD最大的机遇和最大的风险都与毛利率有关。AMD今年的收入加速和利润率增长强劲，这是我相信AMD可以重估更高的主要原因。但毛利率不可能每个季度增长3-4个PP。如果AMD的毛利率扩张放缓，或者更糟的是，毛利率回落至40%，AMD的股票回报可能会下降。毛利率趋势的逆转将改变我对AMD的看法，并使我120美元的股价目标面临危险。</blockquote></p><p> Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p><p><blockquote>CPU和图形芯片的平均售价疲软可能会成为煤矿中的金丝雀，并可能预示着AMD终端市场的提前疲软。终端市场疲软意味着AMD的收入增长将放缓，这可能会导致AMD利润估值的盈利乘数降低。我不认为AMD基于盈利被高估，但市场随时可能不同意我的评估。</blockquote></p><p> <b>Final thoughts</b></p><p><blockquote><b>最后的想法</b></blockquote></p><p> AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p><p><blockquote>AMD报告第二季度收入增长和毛利率令人印象深刻。AMD上调指引和环比收入加速表明CPU和GPU的终端市场远强于预期。在平均售价上升的支持下，这可能会导致又一年的收入加速增长，AMD的毛利率持续扩大至50%。AMD的风险状况仍然严重偏向上行。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-07-30 17:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>AMD's margin gains are driven by growing strength in end markets.</li>  <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>  <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>  <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p><p><blockquote><ul><li>AMD的利润率增长是由终端市场实力的增强推动的。</li><li>AMD将2021财年的收入指引上调了$1.0 B，毛利率接近50%。</li><li>即使增长放缓，这家半导体公司明年的自由现金流也可能达到$6.0 B。</li><li>AMD的美元销售额增长比Nvidia便宜，而且AMD的增长速度甚至可能更快。</li></ul><p class=\"t-img-caption\"><span>Jay_Zynism/iStock来自Getty Images</span></p></blockquote></p><p> AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p><p><blockquote>AMD(AMD)昨天引起了轰动，此前这家半导体公司公布的增长和利润率甚至好于预期。AMD的收入加速和毛利率强劲扩张为该股的上涨提供了强有力的理由。</blockquote></p><p> <b>Why AMD is worth $120</b></p><p><blockquote><b>为什么AMD值120美元</b></blockquote></p><p> Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p><p><blockquote>在我深入了解AMD的最新业绩之前，让我们快速回顾一下该公司上季度的指引。对于21年第二季度，AMD预计收入至少为$3.5 B，“高案例”指导意味着收入环比增长7%，毛利率为47%。</blockquote></p><p> I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p><p><blockquote>我预计AMD的收入将达到指导上限（$3.7 B），最低自由现金流为8.95亿美元（环比增长8%），自由现金流利润率为24%。鉴于价格较高的锐龙台式机和笔记本处理器和GPU的销售加速，以及终端市场广泛实力推动的平均售价/ASP上升，我预计AMD将超出自己的利润率指导，并报告毛利率21年第二季度为48%。我还预测，由于CPU和GPU平均售价的强劲，AMD的毛利率指引将会更新。我在《AMD：迈向50亿美元的年度自由现金流》中详细阐述了对AMD 21年第二季度收益的预测。</blockquote></p><p> Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p><p><blockquote>谈到AMD的实际业绩，这家半导体公司再次证明了它正在全力以赴。AMD 21年第二季度的收入为38.5亿美元，比指导上限高出1.5亿美元，环比增长12%，图形/计算和企业市场的收入势头仍在继续。由于客户端和图形处理器销售额的增加以及平均售价的提高，图形/计算收入环比增长7%，达到22.5亿美元。企业业务已成为AMD近几个季度销售增长的驱动力，21年第二季度收入为$1.6 B，环比增长19%。继AMD在21年第一季度录得5%的季度收入增长后，企业收入在21年第二季度继续加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p><p><blockquote>然而，AMD 21年第二季度收益中最有趣的启示是毛利率的趋势。AMD的毛利率跃升4个百分点至48%，比指导值高出1个百分点，原因是价格较高的锐龙处理器（移动和桌面）和镭龙显卡的更好组合。21年第二季度毛利率的上升标志着AMD利润率连续第三个季度扩张，我认为AMD还没有看到这一趋势的结束。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> Turning to cash flow.</p><p><blockquote>转向现金流。</blockquote></p><p> AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p><p><blockquote>AMD报告的经营活动现金流为9.52亿美元，自由现金流为8.88亿美元，比我的预期低700万美元，但仍是一年前的近六倍。随着AMD在计算/图形和企业终端市场继续看到强劲的收入增长，我相信AMD可以在明年年底前将其自由现金流利润率提高到30%。AMD将2021财年的收入指引（稍后讨论）提高了$1.0 B，这意味着我也刷新了今年和明年的自由现金流预期。</blockquote></p><p> AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p><p><blockquote>AMD预计今年的收入为$15.6 B。假设稳定的自由现金流利润率为23-24%，AMD预计自由现金流为$3.6 B至$3.7 B。明年的收入预期尚未更新，但AMD在2022财年的收入应至少为$20B（假设同比增长25%），这意味着明年的自由现金流为$4.6 B至$4.8 B……而这些预期并未考虑AMD第三代EPYC Milan驱动的服务器处理器和价格更高的GPU提高AMD自由现金流利润率的可能性。明年30%的自由现金流利润率意味着自由现金流为$6.0 B。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p><p><blockquote><table><tbody><tr></tr></tbody></table>AMD预计收入为41亿美元+/-1亿美元，该公司更新了2021财年收入和毛利率指引（如预期）。AMD目前预计2021财年收入增长60%（之前为50%），毛利率为48%（之前为47%）。假设收入增长60%，AMD目前预计全年收入为$15.6 B（之前为$14.6 B），因此AMD的新指导评级为$1.0 B的额外收入，这些收入迄今为止尚未计入AMD的市值。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p><p><blockquote>AMD较高的毛利率和销售指引为该公司股票升值创造了强大的力量。由于AMD股价最近下跌以及收入增加了$1.0 B，AMD的美元销售额增长在盈利后变得更加便宜。AMD的美元销售额增长低于Nvidia，而且AMD的增长速度可能更快：AMD的收入指导评级为同比增长60%，对Nvidia的预测意味着2021财年“仅”同比增长49%。AMD的市值与市盈率为42.5，对于一家收入增长60%、毛利率接近50%的公司来说，这是很低的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p><p><blockquote><table><tbody><tr></tr></tbody></table>基于2022财年每股收益17.29美元，Nvidia的市盈率为44.5。如果AMD的盈利增长（2022财年每股收益为2.71美元）与Nvidia的估值相同，AMD的公平价格将为120美元（2.71美元x 44.5盈利乘数系数），表明上涨空间为17%。</blockquote></p><p> <b>Challenges to my price target</b></p><p><blockquote><b>我的价格目标面临的挑战</b></blockquote></p><p> The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p><p><blockquote>AMD最大的机遇和最大的风险都与毛利率有关。AMD今年的收入加速和利润率增长强劲，这是我相信AMD可以重估更高的主要原因。但毛利率不可能每个季度增长3-4个PP。如果AMD的毛利率扩张放缓，或者更糟的是，毛利率回落至40%，AMD的股票回报可能会下降。毛利率趋势的逆转将改变我对AMD的看法，并使我120美元的股价目标面临危险。</blockquote></p><p> Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p><p><blockquote>CPU和图形芯片的平均售价疲软可能会成为煤矿中的金丝雀，并可能预示着AMD终端市场的提前疲软。终端市场疲软意味着AMD的收入增长将放缓，这可能会导致AMD利润估值的盈利乘数降低。我不认为AMD基于盈利被高估，但市场随时可能不同意我的评估。</blockquote></p><p> <b>Final thoughts</b></p><p><blockquote><b>最后的想法</b></blockquote></p><p> AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p><p><blockquote>AMD报告第二季度收入增长和毛利率令人印象深刻。AMD上调指引和环比收入加速表明CPU和GPU的终端市场远强于预期。在平均售价上升的支持下，这可能会导致又一年的收入加速增长，AMD的毛利率持续扩大至50%。AMD的风险状况仍然严重偏向上行。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175572382,"gmtCreate":1627044519946,"gmtModify":1633768518542,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175572382","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158139403,"gmtCreate":1625134833002,"gmtModify":1633944424001,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158139403","repostId":"1178516480","repostType":4,"repost":{"id":"1178516480","kind":"news","pubTimestamp":1625094708,"share":"https://www.laohu8.com/m/news/1178516480?lang=zh_CN&edition=full","pubTime":"2021-07-01 07:11","market":"us","language":"en","title":"S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178516480","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as inves","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 notches fifth straight record closing high, fifth straight quarterly gain<blockquote>标普500连续第五次创下收盘新高，连续第五个季度上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-01 07:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>NEW YORK (Reuters) - The S&amp;P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.</p><p><blockquote>纽约（路透社）-标普500周三连续第五次创下收盘新高，投资者在本月和本季度结束时基本上摆脱了积极的经济数据，并期待周五备受期待的就业报告。</blockquote></p><p> In the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.</p><p><blockquote>在2021年上半年的最后一个交易日，股指低迷且区间震荡，蓝筹股道指上涨，而纳斯达克则小幅走低。</blockquote></p><p> All three indexes posted their fifth consecutive quarterly gains, with the S&amp;P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&amp;P 500 registered its second-best first-half performance since 1998, rising 14.5%.</p><p><blockquote>三大指数均连续第五个季度上涨，标准普尔指数上涨8.2%，纳斯达克指数上涨9.5%，道指上涨4.6%。标普500上半年表现为1998年以来第二好，上涨14.5%。</blockquote></p><p> “It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&amp;P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”</p><p><blockquote>“这是一个不错的季度，”康涅狄格州费尔菲尔德Dakota Wealth的高级投资组合经理罗伯特·帕夫利克(Robert Pavlik)表示。“截至昨晚收盘，标普今年迄今已上涨超过14%，超过道指和纳斯达克。这表明股市正在出现广泛反弹。”</blockquote></p><p> For the month, the bellwether S&amp;P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.</p><p><blockquote>本月，领头羊标普500连续第五次上涨，而道琼斯指数结束了四个月的连涨，小幅收低。纳斯达克在6月份也取得了进展。</blockquote></p><p> This month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.</p><p><blockquote>本月，投资者的兴趣从对经济敏感的周期性股票转向成长型股票。</blockquote></p><p> “Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”</p><p><blockquote>“今年迄今为止的领先行业正如你所预期的那样，”帕夫利克补充道。“能源、金融和工业，这表明经济环境正处于周期的早期阶段。”</blockquote></p><p> “(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.</p><p><blockquote>帕夫利克补充道：“在人们开始接受（美联储主席杰罗姆）鲍威尔关注暂时性通胀的言论后，（投资者）开始转向增长（股票）。”</blockquote></p><p> “Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”</p><p><blockquote>“一些重新开放的交易已经持续了一段时间，这正在引导人们恢复增长。”</blockquote></p><p> (Graphic: Growths stocks outperform value in June, narrow YTD gap, )</p><p><blockquote>（图：6月份成长股跑赢价值股，年初至今差距缩小，）</blockquote></p><p> <img src=\"https://static.tigerbbs.com/5b82b4dfdc765d913811f9d8572e60f6\" tg-width=\"964\" tg-height=\"723\" referrerpolicy=\"no-referrer\">“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”</p><p><blockquote>纽约Inverness Counsel首席投资策略师蒂姆·格里斯基(Tim Ghriskey)表示：“整体股市继续上涨，在相当长一段时间内持续上涨。”“虽然按照历史标准来看估值肯定很高，但受益于经济复苏，估值一直处于相当稳定的水平。”</blockquote></p><p> The private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.</p><p><blockquote>根据薪资处理机构ADP的数据，私营部门6月份增加了692,000个就业岗位，轻松超出预期。这一数字比经济学家在劳工部周五发布的更全面的就业报告中预测的私人就业人数高出92,000人。</blockquote></p><p> The Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&amp;P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.</p><p><blockquote>道琼斯工业平均指数上涨210.22点，涨幅0.61%，至34,502.51点；标普500上涨5.7点，涨幅0.13%，至4,297.5点；纳斯达克综合指数下跌24.38点，涨幅0.17%，至14,503.95点。</blockquote></p><p> Among the 11 major sectors in the S&amp;P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.</p><p><blockquote>在标准普尔11个主要板块中，有6个板块收高，其中能源板块涨幅最大。房地产是当天最大的输家。</blockquote></p><p> Boeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.</p><p><blockquote>德国国防部宣布将购买该飞机制造商的五架P-8A海上控制飞机，波音公司股价上涨1.6%，此前联合航空公布了有史以来最大的新飞机订单。</blockquote></p><p> Walmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.</p><p><blockquote>沃尔玛周二宣布将开始销售仅限处方的胰岛素类似物，股价上涨2.7%。</blockquote></p><p> Micron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.</p><p><blockquote>美光科技在季度财报发布前上涨2.5%，但在芯片制造商公布季度业绩后，盘后交易中相对没有变化。</blockquote></p><p> Advancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所上涨股与下跌股的比例为1.35比1；在纳斯达克，1.19比1的比率有利于下跌股。</blockquote></p><p> The S&amp;P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.</p><p><blockquote>标普500创下20个52周新高，无新低；纳斯达克综合指数录得70个新高和36个新低。</blockquote></p><p> Volume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.</p><p><blockquote>美国交易所成交量为108.5亿股，而过去20个交易日的平均成交量为110.5亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/us-usa-stocks/sp-500-notches-fifth-straight-record-closing-high-fifth-straight-quarterly-gain-idUSKCN2E619R","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178516480","content_text":"NEW YORK (Reuters) - The S&P 500 nabbed its fifth straight record closing high on Wednesday as investors ended the month and the quarter by largely shrugging off positive economic data and looking toward Friday’s highly anticipated employment report.\nIn the last session of 2021’s first half, the indexes were languid and range-bound, with the blue-chip Dow posting gains, while the Nasdaq edged lower.\nAll three indexes posted their fifth consecutive quarterly gains, with the S&P rising 8.2%, the Nasdaq advancing 9.5% and the Dow rising 4.6%. The S&P 500 registered its second-best first-half performance since 1998, rising 14.5%.\n“It’s been a good quarter,” said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. “As of last night’s close, the S&P has gained more than 14% year-to-date, topping the Dow and the Nasdaq. That indicates that the stock market is having a broad rally.”\nFor the month, the bellwether S&P 500 notched its fifth consecutive advance, while the Dow snapped its four-month winning streak to end slightly lower. The Nasdaq also gained ground in June.\nThis month, investor appetite shifted away from economically sensitive cyclicals in favor of growth stocks.\n“Leading sectors year-to-date are what you’d expect,” Pavlik added. “Energy, financials and industrials, and that speaks to an economic environment that’s in the early stages of a cycle.”\n“(Investors) started the switch back to growth (stocks) after people started to buy in to (Fed Chair Jerome) Powell’s comments that focus on transitory inflation,” Pavlik added.\n“Some of the reopening trades have gotten a bit long in the tooth and that’s leading people back to growth.”\n(Graphic: Growths stocks outperform value in June, narrow YTD gap, )\n“The overall stock market continues to be on a tear, with very consistent gains for quite some time,” said Tim Ghriskey, chief investment strategist at Inverness Counsel in New York. “Valuations, while certainly high by historical standards, have been at a fairly consistent level, benefiting from the economic recovery.”\nThe private sector added 692,000 jobs in June, breezing past expectations, according to payroll processor ADP. The number is 92,000 higher than the private payroll adds economists predict from the Labor Department’s more comprehensive employment report due on Friday.\nThe Dow Jones Industrial Average rose 210.22 points, or 0.61%, to 34,502.51, the S&P 500 gained 5.7 points, or 0.13%, to 4,297.5 and the Nasdaq Composite dropped 24.38 points, or 0.17%, to 14,503.95.\nAmong the 11 major sectors in the S&P, six ended the session higher, with energy enjoying the biggest percentage gain. Real estate was the day’s biggest loser.\nBoeing Co gained 1.6% after Germany’s defense ministry announced it would buy five of the planemaker’s P-8A maritime control aircraft, coming on the heels of United Airlines unveiling its largest-ever order for new planes.\nWalmart jumped 2.7% after announcing on Tuesday that it would start selling a prescription-only insulin analog.\nMicron Technology advanced 2.5% ahead of its quarterly earnings release, but was relatively unchanged in after-hours trading following the chipmaker’s quarterly results.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.19-to-1 ratio favored decliners.\nThe S&P 500 posted 20 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 36 new lows.\nVolume on U.S. exchanges was 10.85 billion shares, compared with the 11.05 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".DJI":0.9,".SPX":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":750,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151033711,"gmtCreate":1625056532133,"gmtModify":1633945394672,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557838603033373","authorIdStr":"3557838603033373"},"themes":[],"htmlText":"Buy All","listText":"Buy All","text":"Buy All","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/151033711","repostId":"1153621389","repostType":4,"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":371162287,"gmtCreate":1618921575449,"gmtModify":1634289903336,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Booster","listText":"Booster","text":"Booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/371162287","repostId":"1185485095","repostType":4,"isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175572382,"gmtCreate":1627044519946,"gmtModify":1633768518542,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175572382","repostId":"1164478982","repostType":4,"isVote":1,"tweetType":1,"viewCount":944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105445400,"gmtCreate":1620323554900,"gmtModify":1634206084849,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Up or down?&nbsp;","listText":"Up or down?&nbsp;","text":"Up or down?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/105445400","repostId":"2133387578","repostType":4,"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":345099607,"gmtCreate":1618251374009,"gmtModify":1634294159460,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Up down up down.&nbsp;","listText":"Up down up down.&nbsp;","text":"Up down up down.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/345099607","repostId":"1188840982","repostType":4,"repost":{"id":"1188840982","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618237983,"share":"https://www.laohu8.com/m/news/1188840982?lang=zh_CN&edition=full","pubTime":"2021-04-12 22:33","market":"us","language":"en","title":"GameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade<blockquote>游戏驿站暴跌逾10%，游戏驿站怀疑论者警告Reddit涨势将消退</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188840982","media":"Tiger Newspress","summary":"(April 12) GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares","content":"<p>(April 12)&nbsp;GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.</p><p><blockquote>（4月12日）游戏驿站暴跌逾10%，游戏驿站怀疑论者警告Reddit涨势将消退；股价暴跌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0e0e81ec43e109abaa82e6aae6fe9a36\" tg-width=\"663\" tg-height=\"564\">GameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.</p><p><blockquote>一位持怀疑态度的华尔街分析师表示，随着数字游戏下载的威胁逐渐加深，游戏驿站公司在Reddit推动下的交易激增可能会消退。</blockquote></p><p> The stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.</p><p><blockquote>Ascendiant Capital Markets分析师Edward Woo将该零售商的评级从持有下调至卖出，称鉴于游戏驿站的市场份额微乎其微，增加视频游戏发行商的数字销售是一个迫在眉睫的风险，随后该股暴跌。他在一份报告中警告客户，随着微软公司和索尼集团公司推出新游戏系统后新游戏系统市场的成熟，该公司的长期前景将受到影响。</blockquote></p><p> The video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.</p><p><blockquote>截至周五收盘，这家视频游戏零售商今年股价飙升741%，将其市值推至110亿美元，然而，Woo预计，从长远来看，股价将暴跌，“以匹配其当前疲软的业绩和前景”。他将目标价从12美元下调至10美元，这意味着较周五收盘价158.36美元下跌了94%。</blockquote></p><p> Shares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.</p><p><blockquote>纽约时间上午9点58分，这家总部位于德克萨斯州格雷普韦恩的公司股价扭转了最初的涨幅，暴跌11%。在一家公司计划出售高达10亿美元的额外股票后，该股在过去六个交易日中下跌了四分之一。</blockquote></p><p> Ascendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”</p><p><blockquote>Ascendiant呼吁游戏驿站在Reddit聊天板和Robinhood投资者中越来越受欢迎，因为他们根据“散户投资者的情绪、希望、势头和人群的力量”而不是基本指标进行股票交易。吴确实承认，这种狂热可能会在短期内推动股价大幅上涨，使得短期价格预测“几乎不可能”。</blockquote></p><p> The stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.</p><p><blockquote>彭博社汇编的数据显示，该股目前有五个卖出评级，而两个持有评级和零买入评级。46.50美元的平均目标价意味着未来一年股价将损失三分之二以上。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade<blockquote>游戏驿站暴跌逾10%，游戏驿站怀疑论者警告Reddit涨势将消退</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop plunged more than 10%, GameStop Skeptic Warns That Reddit Rally Will Fade<blockquote>游戏驿站暴跌逾10%，游戏驿站怀疑论者警告Reddit涨势将消退</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-12 22:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(April 12)&nbsp;GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.</p><p><blockquote>（4月12日）游戏驿站暴跌逾10%，游戏驿站怀疑论者警告Reddit涨势将消退；股价暴跌。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/0e0e81ec43e109abaa82e6aae6fe9a36\" tg-width=\"663\" tg-height=\"564\">GameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.</p><p><blockquote>一位持怀疑态度的华尔街分析师表示，随着数字游戏下载的威胁逐渐加深，游戏驿站公司在Reddit推动下的交易激增可能会消退。</blockquote></p><p> The stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.</p><p><blockquote>Ascendiant Capital Markets分析师Edward Woo将该零售商的评级从持有下调至卖出，称鉴于游戏驿站的市场份额微乎其微，增加视频游戏发行商的数字销售是一个迫在眉睫的风险，随后该股暴跌。他在一份报告中警告客户，随着微软公司和索尼集团公司推出新游戏系统后新游戏系统市场的成熟，该公司的长期前景将受到影响。</blockquote></p><p> The video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.</p><p><blockquote>截至周五收盘，这家视频游戏零售商今年股价飙升741%，将其市值推至110亿美元，然而，Woo预计，从长远来看，股价将暴跌，“以匹配其当前疲软的业绩和前景”。他将目标价从12美元下调至10美元，这意味着较周五收盘价158.36美元下跌了94%。</blockquote></p><p> Shares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.</p><p><blockquote>纽约时间上午9点58分，这家总部位于德克萨斯州格雷普韦恩的公司股价扭转了最初的涨幅，暴跌11%。在一家公司计划出售高达10亿美元的额外股票后，该股在过去六个交易日中下跌了四分之一。</blockquote></p><p> Ascendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”</p><p><blockquote>Ascendiant呼吁游戏驿站在Reddit聊天板和Robinhood投资者中越来越受欢迎，因为他们根据“散户投资者的情绪、希望、势头和人群的力量”而不是基本指标进行股票交易。吴确实承认，这种狂热可能会在短期内推动股价大幅上涨，使得短期价格预测“几乎不可能”。</blockquote></p><p> The stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.</p><p><blockquote>彭博社汇编的数据显示，该股目前有五个卖出评级，而两个持有评级和零买入评级。46.50美元的平均目标价意味着未来一年股价将损失三分之二以上。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188840982","content_text":"(April 12) GameStop plunged more than 10%，GameStop Skeptic Warns That Reddit Rally Will Fade; Shares Slump.\nGameStop Corp.’s Reddit-fueled trading surge is likely going to fade as threats from digital game downloads sink in, according to one skeptical Wall Street analyst.\nThe stock slumped after Ascendiant Capital Markets analyst Edward Woo downgraded the retailer to sell from hold, saying increasing digital sales for video-game publishers is a looming risk given GameStop’s minimal market share. He warned clients in a note about the long-term prospects for the company as the market for new gaming systems matures after new launches from Microsoft Corp. and Sony Group Corp.\nThe video-game retailer’s 741% surge this year through Friday’s close pushed its market value to $11 billion, however, Woo expects shares will tumble in the long run “to match its current weak results and outlook.” He trimmed his price target to $10 from $12, implying as much as a 94% drop from Friday’s close at $158.36.\nShares of the Grapevine, Texas-based company reversed initial gains to slump as much as 11% at 9:58 a.m. in New York. The stock has shed a quarter of its value in the past six session after a company plan to sell as much as $1 billion in additional shares.\nAscendiant called out the rise in popularity of GameStop on Reddit chat boards and with Robinhood investors for making shares trade on “retail investors sentiment, hope, momentum, and the powers of crowds” in place of fundamental metrics. Woo did acknowledge the mania can drive shares much higher in the near-term, making short-term price forecasts “nearly impossible.”\nThe stock now has five sell-equivalent ratings, compared to two hold ratings and zero buys, data compiled by Bloomberg show. An average price target of $46.50 implies shares will lose more than two-thirds of their value in the coming year.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377174111,"gmtCreate":1619511122833,"gmtModify":1634212165817,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/377174111","repostId":"2130522345","repostType":4,"repost":{"id":"2130522345","kind":"highlight","pubTimestamp":1619484161,"share":"https://www.laohu8.com/m/news/2130522345?lang=zh_CN&edition=full","pubTime":"2021-04-27 08:42","market":"us","language":"en","title":"AMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?<blockquote>AMD收益：数据中心所有者是在“消化”还是只是不购买英特尔芯片？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2130522345","media":"MarketWatch","summary":"AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined. AMD first launched the EPYC family of server chips in 2017. AMD. Advanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.AMD $$ is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel $$ reported results last week, the market-share leader","content":"<p>AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined</p><p><blockquote>在最大竞争对手的服务器销售额下降后，包括数据中心销售额在内的AMD部门的收入预计将增长近两倍</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/615a522a230f802ea7b3c7554e6a350b\" tg-width=\"1259\" tg-height=\"709\"><span>AMD first launched the EPYC family of server chips in 2017. AMD</span></p><p><blockquote><p class=\"t-img-caption\"><span>AMD于2017年首次推出了EPYC系列服务器芯片。AMD</span></p></blockquote></p><p> Advanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.</p><p><blockquote>据英特尔公司报道，Advanced Micro Devices Inc.的收益将表明数据中心市场是否真正处于“消化”阶段。</blockquote></p><p> AMD <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> reported results last week, the market-share leader noted that the market was just bottoming from a \"digestion phase\" as its data-center sales dropped 20% year-over-year.</p><p><blockquote>AMD<a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>定于周二收盘后公布第一季度收益。当英特尔<a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a>这家市场份额领先者在上周公布的业绩中指出，由于其数据中心销售额同比下降20%，市场刚刚从“消化阶段”触底。</blockquote></p><p> Analysts questioned that characterization of a \"digestion phase,\" however, asking instead if AMD was taking share away from Intel</p><p><blockquote>然而，分析师质疑这种“消化阶段”的描述，而是质疑AMD是否正在从英特尔手中夺走市场份额</blockquote></p><p> Wall Street, on average, expects AMD to report $1.3 billion in enterprise, embedded, and semi-custom sales, the segment containing data-center and gaming-console chips, nearly triple the $348 million the company reported in the year-ago period .</p><p><blockquote>华尔街平均预计AMD的企业、嵌入式和半定制销售额（其中包括数据中心和游戏机芯片）将达到13亿美元，几乎是该公司去年同期报告的3.48亿美元的三倍。</blockquote></p><p> This all comes amid a continuing shortage of microchips to sate demand from global industries, and the companies that make the silicon wafers chip designs use, work to clear waiting lists that span several months.</p><p><blockquote>这一切都发生在微芯片持续短缺的情况下，以满足全球行业的需求，制造芯片设计使用的硅片的公司正在努力清除长达数月的等待名单。</blockquote></p><p> AMD said in its last earnings report that it expected data-center and gaming sales growth to continue well into 2021. AMD is forecast to report $1.89 billion in computing and graphics sales, a relatively modest 31% rise from a year ago.</p><p><blockquote>AMD在上一份财报中表示，预计数据中心和游戏销售增长将持续到2021年。AMD预计将公布18.9亿美元的计算和图形销售额，比一年前相对温和地增长31%。</blockquote></p><p> In early April, shareholders from AMD and Xilinx Inc.&nbsp;approved a $35 billion wrap-up between the two companies. In March, the company announced a&nbsp;new gaming card.</p><p><blockquote>4月初，AMD和Xilinx Inc.的股东批准了两家公司之间350亿美元的合并。三月份，该公司宣布了一款新的游戏卡。</blockquote></p><p> <b>What to expect</b></p><p><blockquote><b>期待什么</b></blockquote></p><p> Earnings: Of the 34 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 44 cents a share, up from 35 cents a share expected at the beginning of the quarter and 18 cents a share reported in the year-ago period. Estimize, a software platform that crowdsources estimates from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 48 cents a share.</p><p><blockquote>盈利：在FactSet调查的34名分析师中，AMD平均预计调整后每股收益为44美分，高于本季度初预期的每股35美分和去年同期报告的每股18美分。Estimize是一个软件平台，众包对冲基金高管、券商、买方分析师和其他人对评级每股收益48美分的估计。</blockquote></p><p> Revenue: Back in January, AMD predicted first-quarter sales between $3.1 billion and $3.3 billion, while analysts on average had forecast revenue of $2.68 billion at the time. Now, 31 analysts, on average, expect revenue of $3.18 billion, up from the $1.79 billion reported in the year-ago quarter. Estimize expects revenue of $3.25 billion.</p><p><blockquote>营收：早在1月份，AMD就预测第一季度销售额在31亿美元至33亿美元之间，而当时分析师平均预测营收为26.8亿美元。目前，31名分析师平均预计营收为31.8亿美元，高于去年同期的17.9亿美元。Estimize预计营收为32.5亿美元。</blockquote></p><p> Stock movement: In the first quarter, AMD shares fell 14.4%. In contrast, the PHLX Semiconductor Index gained 11.8%, the S&amp;P 500 index gained 5.8%, and the tech-heavy Nasdaq Composite Index rose 2.8%.</p><p><blockquote>股票走势：第一季度，AMD股价下跌14.4%。相比之下，PHLX半导体指数上涨11.8%，标普500指数上涨5.8%，以科技股为主的纳斯达克综合指数上涨2.8%。</blockquote></p><p> <b>What analysts are saying</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> Susquehanna Financial analyst Christopher Rolland, who has a positive rating and a $115 price target on AMD, said PC and graphics processing unit checks point to continued strong demand in the first quarter.</p><p><blockquote>Susquehanna Financial分析师Christopher Rolland对AMD给予正面评级，目标价为115美元，他表示，PC和图形处理部门的检查表明第一季度需求持续强劲。</blockquote></p><p> \"While many believe upside is capped by capacity constraints, we believe AMD is quickly becoming [Taiwan Semiconductor Manufacturing Co.'s (2330.TW)] preferred 'CPU' partner, as Intel's IDM 2.0 strategy appears increasingly competitive to thefoundry,\" Rolland said. \"Therefore, we would not be surprised to see AMD receive more than enough wafers to track toward full-year guidance and perhaps beyond.\"</p><p><blockquote>Rolland表示：“虽然许多人认为产能限制限制了上行空间，但我们相信AMD正在迅速成为[台积电公司(2330.TW)]首选的‘CPU’合作伙伴，因为英特尔的IDM 2.0战略似乎对代工厂的竞争力越来越强。”“因此，如果AMD收到足够多的晶圆来跟踪全年指导甚至更长时间，我们不会感到惊讶。”</blockquote></p><p> <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> analyst Joseph Moore, who just reinstated estimates for AMD, said he expects strong earnings above the consensus from AMD with \"strong demand across the board, and supply constraints due to substrates and to a lesser extent wafers.\"</p><p><blockquote><a href=\"https://laohu8.com/S/MSTLW\">摩根士丹利</a>刚刚恢复对AMD预期的分析师约瑟夫·摩尔(Joseph Moore)表示，他预计AMD的盈利将高于市场普遍预期，“全面需求强劲，以及基板和较小程度上晶圆造成的供应限制”。</blockquote></p><p> Moore expects fab priority to keep going to high margin products like servers and \"enthusiast desktop microprocessors\" and \"lowest-margin customers that are strategic and sole sourced\" like Microsoft Corp.'s <a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a> and Sony Group Corp.'s gaming consoles.</p><p><blockquote>摩尔预计晶圆厂将继续优先考虑服务器和“发烧友桌面微处理器”等高利润产品，以及微软公司等“利润最低的战略和独家采购客户”<a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a>和索尼集团公司的游戏机。</blockquote></p><p> \"With competitors also dealing with supply constraints, overall pricing should be healthy,\" Moore said. The analysts expects AMD fiscal earnings of $2.04 a share in 2021, $2.59 a share in 2022, and $2.90 a share in 2023, while analysts surveyed by FactSet expect per-share earnings of $1.95, $2.51, and $3.23, respectively.</p><p><blockquote>摩尔表示：“由于竞争对手也面临供应限制，整体定价应该是健康的。”分析师预计AMD 2021财年每股收益为2.04美元，2022财年每股收益为2.59美元，2023财年每股收益为2.90美元，而FactSet调查的分析师预计每股收益分别为1.95美元、2.51美元和3.23美元。</blockquote></p><p> B of A Securities analyst Vivek Arya, who has a $100 price target, said of the larger chip market that \"Supply constraints could limit Q1 outperformance/Q2 outlook, but extend cycle into CY22\"</p><p><blockquote>B of A Securities分析师Vivek Arya的目标价为100美元，他在谈到更大的芯片市场时表示，“供应限制可能会限制第一季度的优异表现/第二季度的前景，但会将周期延长至2022年”</blockquote></p><p> For AMD, \"can it obtain enough incremental supply from TSMC to beat its already robust 37% YoY sales outlook for CY21 while firmly convincing investors around INTC share gains?\"</p><p><blockquote>对于AMD来说，“它能否从台积电获得足够的增量供应，以超越其本已强劲的2021年同比37%的销售前景，同时坚定地说服投资者相信INTC股价上涨？”</blockquote></p><p></p><p> Of the 36 analysts who cover AMD, 21 have buy or overweight ratings, 12 have hold ratings and three have sell ratings, with an average price target of $100.50.</p><p><blockquote>在关注AMD的36名分析师中，21名给予买入或跑赢大盘评级，12名给予持有评级，3名给予卖出评级，平均目标价为100.50美元。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?<blockquote>AMD收益：数据中心所有者是在“消化”还是只是不购买英特尔芯片？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD earnings: Are data center owners ‘digesting’ or just not buying Intel chips?<blockquote>AMD收益：数据中心所有者是在“消化”还是只是不购买英特尔芯片？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-04-27 08:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p>AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined</p><p><blockquote>在最大竞争对手的服务器销售额下降后，包括数据中心销售额在内的AMD部门的收入预计将增长近两倍</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/615a522a230f802ea7b3c7554e6a350b\" tg-width=\"1259\" tg-height=\"709\"><span>AMD first launched the EPYC family of server chips in 2017. AMD</span></p><p><blockquote><p class=\"t-img-caption\"><span>AMD于2017年首次推出了EPYC系列服务器芯片。AMD</span></p></blockquote></p><p> Advanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.</p><p><blockquote>据英特尔公司报道，Advanced Micro Devices Inc.的收益将表明数据中心市场是否真正处于“消化”阶段。</blockquote></p><p> AMD <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> reported results last week, the market-share leader noted that the market was just bottoming from a \"digestion phase\" as its data-center sales dropped 20% year-over-year.</p><p><blockquote>AMD<a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>定于周二收盘后公布第一季度收益。当英特尔<a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a>这家市场份额领先者在上周公布的业绩中指出，由于其数据中心销售额同比下降20%，市场刚刚从“消化阶段”触底。</blockquote></p><p> Analysts questioned that characterization of a \"digestion phase,\" however, asking instead if AMD was taking share away from Intel</p><p><blockquote>然而，分析师质疑这种“消化阶段”的描述，而是质疑AMD是否正在从英特尔手中夺走市场份额</blockquote></p><p> Wall Street, on average, expects AMD to report $1.3 billion in enterprise, embedded, and semi-custom sales, the segment containing data-center and gaming-console chips, nearly triple the $348 million the company reported in the year-ago period .</p><p><blockquote>华尔街平均预计AMD的企业、嵌入式和半定制销售额（其中包括数据中心和游戏机芯片）将达到13亿美元，几乎是该公司去年同期报告的3.48亿美元的三倍。</blockquote></p><p> This all comes amid a continuing shortage of microchips to sate demand from global industries, and the companies that make the silicon wafers chip designs use, work to clear waiting lists that span several months.</p><p><blockquote>这一切都发生在微芯片持续短缺的情况下，以满足全球行业的需求，制造芯片设计使用的硅片的公司正在努力清除长达数月的等待名单。</blockquote></p><p> AMD said in its last earnings report that it expected data-center and gaming sales growth to continue well into 2021. AMD is forecast to report $1.89 billion in computing and graphics sales, a relatively modest 31% rise from a year ago.</p><p><blockquote>AMD在上一份财报中表示，预计数据中心和游戏销售增长将持续到2021年。AMD预计将公布18.9亿美元的计算和图形销售额，比一年前相对温和地增长31%。</blockquote></p><p> In early April, shareholders from AMD and Xilinx Inc.&nbsp;approved a $35 billion wrap-up between the two companies. In March, the company announced a&nbsp;new gaming card.</p><p><blockquote>4月初，AMD和Xilinx Inc.的股东批准了两家公司之间350亿美元的合并。三月份，该公司宣布了一款新的游戏卡。</blockquote></p><p> <b>What to expect</b></p><p><blockquote><b>期待什么</b></blockquote></p><p> Earnings: Of the 34 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 44 cents a share, up from 35 cents a share expected at the beginning of the quarter and 18 cents a share reported in the year-ago period. Estimize, a software platform that crowdsources estimates from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 48 cents a share.</p><p><blockquote>盈利：在FactSet调查的34名分析师中，AMD平均预计调整后每股收益为44美分，高于本季度初预期的每股35美分和去年同期报告的每股18美分。Estimize是一个软件平台，众包对冲基金高管、券商、买方分析师和其他人对评级每股收益48美分的估计。</blockquote></p><p> Revenue: Back in January, AMD predicted first-quarter sales between $3.1 billion and $3.3 billion, while analysts on average had forecast revenue of $2.68 billion at the time. Now, 31 analysts, on average, expect revenue of $3.18 billion, up from the $1.79 billion reported in the year-ago quarter. Estimize expects revenue of $3.25 billion.</p><p><blockquote>营收：早在1月份，AMD就预测第一季度销售额在31亿美元至33亿美元之间，而当时分析师平均预测营收为26.8亿美元。目前，31名分析师平均预计营收为31.8亿美元，高于去年同期的17.9亿美元。Estimize预计营收为32.5亿美元。</blockquote></p><p> Stock movement: In the first quarter, AMD shares fell 14.4%. In contrast, the PHLX Semiconductor Index gained 11.8%, the S&amp;P 500 index gained 5.8%, and the tech-heavy Nasdaq Composite Index rose 2.8%.</p><p><blockquote>股票走势：第一季度，AMD股价下跌14.4%。相比之下，PHLX半导体指数上涨11.8%，标普500指数上涨5.8%，以科技股为主的纳斯达克综合指数上涨2.8%。</blockquote></p><p> <b>What analysts are saying</b></p><p><blockquote><b>分析师怎么说</b></blockquote></p><p> Susquehanna Financial analyst Christopher Rolland, who has a positive rating and a $115 price target on AMD, said PC and graphics processing unit checks point to continued strong demand in the first quarter.</p><p><blockquote>Susquehanna Financial分析师Christopher Rolland对AMD给予正面评级，目标价为115美元，他表示，PC和图形处理部门的检查表明第一季度需求持续强劲。</blockquote></p><p> \"While many believe upside is capped by capacity constraints, we believe AMD is quickly becoming [Taiwan Semiconductor Manufacturing Co.'s (2330.TW)] preferred 'CPU' partner, as Intel's IDM 2.0 strategy appears increasingly competitive to thefoundry,\" Rolland said. \"Therefore, we would not be surprised to see AMD receive more than enough wafers to track toward full-year guidance and perhaps beyond.\"</p><p><blockquote>Rolland表示：“虽然许多人认为产能限制限制了上行空间，但我们相信AMD正在迅速成为[台积电公司(2330.TW)]首选的‘CPU’合作伙伴，因为英特尔的IDM 2.0战略似乎对代工厂的竞争力越来越强。”“因此，如果AMD收到足够多的晶圆来跟踪全年指导甚至更长时间，我们不会感到惊讶。”</blockquote></p><p> <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> analyst Joseph Moore, who just reinstated estimates for AMD, said he expects strong earnings above the consensus from AMD with \"strong demand across the board, and supply constraints due to substrates and to a lesser extent wafers.\"</p><p><blockquote><a href=\"https://laohu8.com/S/MSTLW\">摩根士丹利</a>刚刚恢复对AMD预期的分析师约瑟夫·摩尔(Joseph Moore)表示，他预计AMD的盈利将高于市场普遍预期，“全面需求强劲，以及基板和较小程度上晶圆造成的供应限制”。</blockquote></p><p> Moore expects fab priority to keep going to high margin products like servers and \"enthusiast desktop microprocessors\" and \"lowest-margin customers that are strategic and sole sourced\" like Microsoft Corp.'s <a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a> and Sony Group Corp.'s gaming consoles.</p><p><blockquote>摩尔预计晶圆厂将继续优先考虑服务器和“发烧友桌面微处理器”等高利润产品，以及微软公司等“利润最低的战略和独家采购客户”<a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a>和索尼集团公司的游戏机。</blockquote></p><p> \"With competitors also dealing with supply constraints, overall pricing should be healthy,\" Moore said. The analysts expects AMD fiscal earnings of $2.04 a share in 2021, $2.59 a share in 2022, and $2.90 a share in 2023, while analysts surveyed by FactSet expect per-share earnings of $1.95, $2.51, and $3.23, respectively.</p><p><blockquote>摩尔表示：“由于竞争对手也面临供应限制，整体定价应该是健康的。”分析师预计AMD 2021财年每股收益为2.04美元，2022财年每股收益为2.59美元，2023财年每股收益为2.90美元，而FactSet调查的分析师预计每股收益分别为1.95美元、2.51美元和3.23美元。</blockquote></p><p> B of A Securities analyst Vivek Arya, who has a $100 price target, said of the larger chip market that \"Supply constraints could limit Q1 outperformance/Q2 outlook, but extend cycle into CY22\"</p><p><blockquote>B of A Securities分析师Vivek Arya的目标价为100美元，他在谈到更大的芯片市场时表示，“供应限制可能会限制第一季度的优异表现/第二季度的前景，但会将周期延长至2022年”</blockquote></p><p> For AMD, \"can it obtain enough incremental supply from TSMC to beat its already robust 37% YoY sales outlook for CY21 while firmly convincing investors around INTC share gains?\"</p><p><blockquote>对于AMD来说，“它能否从台积电获得足够的增量供应，以超越其本已强劲的2021年同比37%的销售前景，同时坚定地说服投资者相信INTC股价上涨？”</blockquote></p><p></p><p> Of the 36 analysts who cover AMD, 21 have buy or overweight ratings, 12 have hold ratings and three have sell ratings, with an average price target of $100.50.</p><p><blockquote>在关注AMD的36名分析师中，21名给予买入或跑赢大盘评级，12名给予持有评级，3名给予卖出评级，平均目标价为100.50美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/amd-earnings-are-data-center-owners-digesting-or-just-not-buying-intel-chips-11619473180?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.marketwatch.com/story/amd-earnings-are-data-center-owners-digesting-or-just-not-buying-intel-chips-11619473180?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2130522345","content_text":"AMD segment that includes data-center sales expected to almost triple in revenue after biggest rival's server sales declined\nAMD first launched the EPYC family of server chips in 2017. AMD\nAdvanced Micro Devices Inc. earnings will serve as an indication if the data-center market is truly in a \"digestion\" phase, as Intel Corp. reported.\nAMD $(AMD)$ is scheduled to report its first-quarter earnings on Tuesday after the close of markets. When Intel $(INTC)$ reported results last week, the market-share leader noted that the market was just bottoming from a \"digestion phase\" as its data-center sales dropped 20% year-over-year.\nAnalysts questioned that characterization of a \"digestion phase,\" however, asking instead if AMD was taking share away from Intel\nWall Street, on average, expects AMD to report $1.3 billion in enterprise, embedded, and semi-custom sales, the segment containing data-center and gaming-console chips, nearly triple the $348 million the company reported in the year-ago period .\nThis all comes amid a continuing shortage of microchips to sate demand from global industries, and the companies that make the silicon wafers chip designs use, work to clear waiting lists that span several months.\nAMD said in its last earnings report that it expected data-center and gaming sales growth to continue well into 2021. AMD is forecast to report $1.89 billion in computing and graphics sales, a relatively modest 31% rise from a year ago.\nIn early April, shareholders from AMD and Xilinx Inc. approved a $35 billion wrap-up between the two companies. In March, the company announced a new gaming card.\nWhat to expect\nEarnings: Of the 34 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 44 cents a share, up from 35 cents a share expected at the beginning of the quarter and 18 cents a share reported in the year-ago period. Estimize, a software platform that crowdsources estimates from hedge-fund executives, brokerages, buy-side analysts and others, calls for earnings of 48 cents a share.\nRevenue: Back in January, AMD predicted first-quarter sales between $3.1 billion and $3.3 billion, while analysts on average had forecast revenue of $2.68 billion at the time. Now, 31 analysts, on average, expect revenue of $3.18 billion, up from the $1.79 billion reported in the year-ago quarter. Estimize expects revenue of $3.25 billion.\nStock movement: In the first quarter, AMD shares fell 14.4%. In contrast, the PHLX Semiconductor Index gained 11.8%, the S&P 500 index gained 5.8%, and the tech-heavy Nasdaq Composite Index rose 2.8%.\nWhat analysts are saying\nSusquehanna Financial analyst Christopher Rolland, who has a positive rating and a $115 price target on AMD, said PC and graphics processing unit checks point to continued strong demand in the first quarter.\n\"While many believe upside is capped by capacity constraints, we believe AMD is quickly becoming [Taiwan Semiconductor Manufacturing Co.'s (2330.TW)] preferred 'CPU' partner, as Intel's IDM 2.0 strategy appears increasingly competitive to thefoundry,\" Rolland said. \"Therefore, we would not be surprised to see AMD receive more than enough wafers to track toward full-year guidance and perhaps beyond.\"\nMorgan Stanley analyst Joseph Moore, who just reinstated estimates for AMD, said he expects strong earnings above the consensus from AMD with \"strong demand across the board, and supply constraints due to substrates and to a lesser extent wafers.\"\nMoore expects fab priority to keep going to high margin products like servers and \"enthusiast desktop microprocessors\" and \"lowest-margin customers that are strategic and sole sourced\" like Microsoft Corp.'s $(MSFT)$ and Sony Group Corp.'s gaming consoles.\n\"With competitors also dealing with supply constraints, overall pricing should be healthy,\" Moore said. The analysts expects AMD fiscal earnings of $2.04 a share in 2021, $2.59 a share in 2022, and $2.90 a share in 2023, while analysts surveyed by FactSet expect per-share earnings of $1.95, $2.51, and $3.23, respectively.\nB of A Securities analyst Vivek Arya, who has a $100 price target, said of the larger chip market that \"Supply constraints could limit Q1 outperformance/Q2 outlook, but extend cycle into CY22\"\nFor AMD, \"can it obtain enough incremental supply from TSMC to beat its already robust 37% YoY sales outlook for CY21 while firmly convincing investors around INTC share gains?\"\nOf the 36 analysts who cover AMD, 21 have buy or overweight ratings, 12 have hold ratings and three have sell ratings, with an average price target of $100.50.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879637577,"gmtCreate":1636715008912,"gmtModify":1636715009013,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Liked","listText":"Liked","text":"Liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879637577","repostId":"1149394295","repostType":4,"repost":{"id":"1149394295","kind":"news","pubTimestamp":1636714672,"share":"https://www.laohu8.com/m/news/1149394295?lang=zh_CN&edition=full","pubTime":"2021-11-12 18:57","market":"us","language":"en","title":"Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149394295","media":"Reuters","summary":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar","content":"<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&amp;Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&amp;Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-12 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &amp;Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&amp;Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTCO":"Natura & Co Holding SA"},"source_url":"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149394295","content_text":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.\nNatura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.\nThe company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.\nIt reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.\nNatura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.\nOn the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.\nHe praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.\nMarques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.\nAccording to Marques, Natura has had a hard time raising prices as key markets deal with these issues.\n\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.","news_type":1,"symbols_score_info":{"NTCO":0.9}},"isVote":1,"tweetType":1,"viewCount":3266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":806132514,"gmtCreate":1627639750838,"gmtModify":1633757542718,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806132514","repostId":"1135561812","repostType":4,"repost":{"id":"1135561812","kind":"news","pubTimestamp":1627637430,"share":"https://www.laohu8.com/m/news/1135561812?lang=zh_CN&edition=full","pubTime":"2021-07-30 17:30","market":"us","language":"en","title":"AMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135561812","media":"seekingalpha","summary":"AMD's margin gains are driven by growing strength in end markets.AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors  and Radeon graphic cards. The uptick in g","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>AMD's margin gains are driven by growing strength in end markets.</li>  <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>  <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>  <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p><p><blockquote><ul><li>AMD的利润率增长是由终端市场实力的增强推动的。</li><li>AMD将2021财年的收入指引上调了$1.0 B，毛利率接近50%。</li><li>即使增长放缓，这家半导体公司明年的自由现金流也可能达到$6.0 B。</li><li>AMD的美元销售额增长比Nvidia便宜，而且AMD的增长速度甚至可能更快。</li></ul><p class=\"t-img-caption\"><span>Jay_Zynism/iStock来自Getty Images</span></p></blockquote></p><p> AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p><p><blockquote>AMD(AMD)昨天引起了轰动，此前这家半导体公司公布的增长和利润率甚至好于预期。AMD的收入加速和毛利率强劲扩张为该股的上涨提供了强有力的理由。</blockquote></p><p> <b>Why AMD is worth $120</b></p><p><blockquote><b>为什么AMD值120美元</b></blockquote></p><p> Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p><p><blockquote>在我深入了解AMD的最新业绩之前，让我们快速回顾一下该公司上季度的指引。对于21年第二季度，AMD预计收入至少为$3.5 B，“高案例”指导意味着收入环比增长7%，毛利率为47%。</blockquote></p><p> I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p><p><blockquote>我预计AMD的收入将达到指导上限（$3.7 B），最低自由现金流为8.95亿美元（环比增长8%），自由现金流利润率为24%。鉴于价格较高的锐龙台式机和笔记本处理器和GPU的销售加速，以及终端市场广泛实力推动的平均售价/ASP上升，我预计AMD将超出自己的利润率指导，并报告毛利率21年第二季度为48%。我还预测，由于CPU和GPU平均售价的强劲，AMD的毛利率指引将会更新。我在《AMD：迈向50亿美元的年度自由现金流》中详细阐述了对AMD 21年第二季度收益的预测。</blockquote></p><p> Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p><p><blockquote>谈到AMD的实际业绩，这家半导体公司再次证明了它正在全力以赴。AMD 21年第二季度的收入为38.5亿美元，比指导上限高出1.5亿美元，环比增长12%，图形/计算和企业市场的收入势头仍在继续。由于客户端和图形处理器销售额的增加以及平均售价的提高，图形/计算收入环比增长7%，达到22.5亿美元。企业业务已成为AMD近几个季度销售增长的驱动力，21年第二季度收入为$1.6 B，环比增长19%。继AMD在21年第一季度录得5%的季度收入增长后，企业收入在21年第二季度继续加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p><p><blockquote>然而，AMD 21年第二季度收益中最有趣的启示是毛利率的趋势。AMD的毛利率跃升4个百分点至48%，比指导值高出1个百分点，原因是价格较高的锐龙处理器（移动和桌面）和镭龙显卡的更好组合。21年第二季度毛利率的上升标志着AMD利润率连续第三个季度扩张，我认为AMD还没有看到这一趋势的结束。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> Turning to cash flow.</p><p><blockquote>转向现金流。</blockquote></p><p> AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p><p><blockquote>AMD报告的经营活动现金流为9.52亿美元，自由现金流为8.88亿美元，比我的预期低700万美元，但仍是一年前的近六倍。随着AMD在计算/图形和企业终端市场继续看到强劲的收入增长，我相信AMD可以在明年年底前将其自由现金流利润率提高到30%。AMD将2021财年的收入指引（稍后讨论）提高了$1.0 B，这意味着我也刷新了今年和明年的自由现金流预期。</blockquote></p><p> AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p><p><blockquote>AMD预计今年的收入为$15.6 B。假设稳定的自由现金流利润率为23-24%，AMD预计自由现金流为$3.6 B至$3.7 B。明年的收入预期尚未更新，但AMD在2022财年的收入应至少为$20B（假设同比增长25%），这意味着明年的自由现金流为$4.6 B至$4.8 B……而这些预期并未考虑AMD第三代EPYC Milan驱动的服务器处理器和价格更高的GPU提高AMD自由现金流利润率的可能性。明年30%的自由现金流利润率意味着自由现金流为$6.0 B。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p><p><blockquote><table><tbody><tr></tr></tbody></table>AMD预计收入为41亿美元+/-1亿美元，该公司更新了2021财年收入和毛利率指引（如预期）。AMD目前预计2021财年收入增长60%（之前为50%），毛利率为48%（之前为47%）。假设收入增长60%，AMD目前预计全年收入为$15.6 B（之前为$14.6 B），因此AMD的新指导评级为$1.0 B的额外收入，这些收入迄今为止尚未计入AMD的市值。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p><p><blockquote>AMD较高的毛利率和销售指引为该公司股票升值创造了强大的力量。由于AMD股价最近下跌以及收入增加了$1.0 B，AMD的美元销售额增长在盈利后变得更加便宜。AMD的美元销售额增长低于Nvidia，而且AMD的增长速度可能更快：AMD的收入指导评级为同比增长60%，对Nvidia的预测意味着2021财年“仅”同比增长49%。AMD的市值与市盈率为42.5，对于一家收入增长60%、毛利率接近50%的公司来说，这是很低的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p><p><blockquote><table><tbody><tr></tr></tbody></table>基于2022财年每股收益17.29美元，Nvidia的市盈率为44.5。如果AMD的盈利增长（2022财年每股收益为2.71美元）与Nvidia的估值相同，AMD的公平价格将为120美元（2.71美元x 44.5盈利乘数系数），表明上涨空间为17%。</blockquote></p><p> <b>Challenges to my price target</b></p><p><blockquote><b>我的价格目标面临的挑战</b></blockquote></p><p> The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p><p><blockquote>AMD最大的机遇和最大的风险都与毛利率有关。AMD今年的收入加速和利润率增长强劲，这是我相信AMD可以重估更高的主要原因。但毛利率不可能每个季度增长3-4个PP。如果AMD的毛利率扩张放缓，或者更糟的是，毛利率回落至40%，AMD的股票回报可能会下降。毛利率趋势的逆转将改变我对AMD的看法，并使我120美元的股价目标面临危险。</blockquote></p><p> Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p><p><blockquote>CPU和图形芯片的平均售价疲软可能会成为煤矿中的金丝雀，并可能预示着AMD终端市场的提前疲软。终端市场疲软意味着AMD的收入增长将放缓，这可能会导致AMD利润估值的盈利乘数降低。我不认为AMD基于盈利被高估，但市场随时可能不同意我的评估。</blockquote></p><p> <b>Final thoughts</b></p><p><blockquote><b>最后的想法</b></blockquote></p><p> AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p><p><blockquote>AMD报告第二季度收入增长和毛利率令人印象深刻。AMD上调指引和环比收入加速表明CPU和GPU的终端市场远强于预期。在平均售价上升的支持下，这可能会导致又一年的收入加速增长，AMD的毛利率持续扩大至50%。AMD的风险状况仍然严重偏向上行。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD: Still Growing, Still Undervalued<blockquote>AMD：仍在增长，仍被低估</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-07-30 17:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>AMD's margin gains are driven by growing strength in end markets.</li>  <li>AMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.</li>  <li>The semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.</li>  <li>AMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e6e179318de667e33987f1b4a2afb27\" tg-width=\"768\" tg-height=\"512\" width=\"100%\" height=\"auto\"><span>Jay_Zynism/iStock via Getty Images</span></p><p><blockquote><ul><li>AMD的利润率增长是由终端市场实力的增强推动的。</li><li>AMD将2021财年的收入指引上调了$1.0 B，毛利率接近50%。</li><li>即使增长放缓，这家半导体公司明年的自由现金流也可能达到$6.0 B。</li><li>AMD的美元销售额增长比Nvidia便宜，而且AMD的增长速度甚至可能更快。</li></ul><p class=\"t-img-caption\"><span>Jay_Zynism/iStock来自Getty Images</span></p></blockquote></p><p> AMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.</p><p><blockquote>AMD(AMD)昨天引起了轰动，此前这家半导体公司公布的增长和利润率甚至好于预期。AMD的收入加速和毛利率强劲扩张为该股的上涨提供了强有力的理由。</blockquote></p><p> <b>Why AMD is worth $120</b></p><p><blockquote><b>为什么AMD值120美元</b></blockquote></p><p> Before I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.</p><p><blockquote>在我深入了解AMD的最新业绩之前，让我们快速回顾一下该公司上季度的指引。对于21年第二季度，AMD预计收入至少为$3.5 B，“高案例”指导意味着收入环比增长7%，毛利率为47%。</blockquote></p><p> I expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.</p><p><blockquote>我预计AMD的收入将达到指导上限（$3.7 B），最低自由现金流为8.95亿美元（环比增长8%），自由现金流利润率为24%。鉴于价格较高的锐龙台式机和笔记本处理器和GPU的销售加速，以及终端市场广泛实力推动的平均售价/ASP上升，我预计AMD将超出自己的利润率指导，并报告毛利率21年第二季度为48%。我还预测，由于CPU和GPU平均售价的强劲，AMD的毛利率指引将会更新。我在《AMD：迈向50亿美元的年度自由现金流》中详细阐述了对AMD 21年第二季度收益的预测。</blockquote></p><p> Turning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.</p><p><blockquote>谈到AMD的实际业绩，这家半导体公司再次证明了它正在全力以赴。AMD 21年第二季度的收入为38.5亿美元，比指导上限高出1.5亿美元，环比增长12%，图形/计算和企业市场的收入势头仍在继续。由于客户端和图形处理器销售额的增加以及平均售价的提高，图形/计算收入环比增长7%，达到22.5亿美元。企业业务已成为AMD近几个季度销售增长的驱动力，21年第二季度收入为$1.6 B，环比增长19%。继AMD在21年第一季度录得5%的季度收入增长后，企业收入在21年第二季度继续加速。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ec3e9d1f0b7d59915f9db8790725803\" tg-width=\"1039\" tg-height=\"587\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> The most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.</p><p><blockquote>然而，AMD 21年第二季度收益中最有趣的启示是毛利率的趋势。AMD的毛利率跃升4个百分点至48%，比指导值高出1个百分点，原因是价格较高的锐龙处理器（移动和桌面）和镭龙显卡的更好组合。21年第二季度毛利率的上升标志着AMD利润率连续第三个季度扩张，我认为AMD还没有看到这一趋势的结束。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dca6426ffa1332827a6774554d499c36\" tg-width=\"1048\" tg-height=\"566\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> Turning to cash flow.</p><p><blockquote>转向现金流。</blockquote></p><p> AMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.</p><p><blockquote>AMD报告的经营活动现金流为9.52亿美元，自由现金流为8.88亿美元，比我的预期低700万美元，但仍是一年前的近六倍。随着AMD在计算/图形和企业终端市场继续看到强劲的收入增长，我相信AMD可以在明年年底前将其自由现金流利润率提高到30%。AMD将2021财年的收入指引（稍后讨论）提高了$1.0 B，这意味着我也刷新了今年和明年的自由现金流预期。</blockquote></p><p> AMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.</p><p><blockquote>AMD预计今年的收入为$15.6 B。假设稳定的自由现金流利润率为23-24%，AMD预计自由现金流为$3.6 B至$3.7 B。明年的收入预期尚未更新，但AMD在2022财年的收入应至少为$20B（假设同比增长25%），这意味着明年的自由现金流为$4.6 B至$4.8 B……而这些预期并未考虑AMD第三代EPYC Milan驱动的服务器处理器和价格更高的GPU提高AMD自由现金流利润率的可能性。明年30%的自由现金流利润率意味着自由现金流为$6.0 B。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6ea23b7429f2edd8ce6dda945a88daa7\" tg-width=\"819\" tg-height=\"593\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> AMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.</p><p><blockquote><table><tbody><tr></tr></tbody></table>AMD预计收入为41亿美元+/-1亿美元，该公司更新了2021财年收入和毛利率指引（如预期）。AMD目前预计2021财年收入增长60%（之前为50%），毛利率为48%（之前为47%）。假设收入增长60%，AMD目前预计全年收入为$15.6 B（之前为$14.6 B），因此AMD的新指导评级为$1.0 B的额外收入，这些收入迄今为止尚未计入AMD的市值。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e5c3c579e4a6472ae2c495a325b9a2b\" tg-width=\"1038\" tg-height=\"572\" width=\"100%\" height=\"auto\"><span>(Source:AMD)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：AMD）</span></p></blockquote></p><p> AMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.</p><p><blockquote>AMD较高的毛利率和销售指引为该公司股票升值创造了强大的力量。由于AMD股价最近下跌以及收入增加了$1.0 B，AMD的美元销售额增长在盈利后变得更加便宜。AMD的美元销售额增长低于Nvidia，而且AMD的增长速度可能更快：AMD的收入指导评级为同比增长60%，对Nvidia的预测意味着2021财年“仅”同比增长49%。AMD的市值与市盈率为42.5，对于一家收入增长60%、毛利率接近50%的公司来说，这是很低的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/653c9dd9d37a4abd742703bd87dd3534\" tg-width=\"908\" tg-height=\"312\" width=\"100%\" height=\"auto\"><span>(Source: Author)</span></p><p><blockquote><p class=\"t-img-caption\"><span>（来源：作者）</span></p></blockquote></p><p> <table>  <tbody>   <tr></tr>  </tbody> </table> Nvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.</p><p><blockquote><table><tbody><tr></tr></tbody></table>基于2022财年每股收益17.29美元，Nvidia的市盈率为44.5。如果AMD的盈利增长（2022财年每股收益为2.71美元）与Nvidia的估值相同，AMD的公平价格将为120美元（2.71美元x 44.5盈利乘数系数），表明上涨空间为17%。</blockquote></p><p> <b>Challenges to my price target</b></p><p><blockquote><b>我的价格目标面临的挑战</b></blockquote></p><p> The biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.</p><p><blockquote>AMD最大的机遇和最大的风险都与毛利率有关。AMD今年的收入加速和利润率增长强劲，这是我相信AMD可以重估更高的主要原因。但毛利率不可能每个季度增长3-4个PP。如果AMD的毛利率扩张放缓，或者更糟的是，毛利率回落至40%，AMD的股票回报可能会下降。毛利率趋势的逆转将改变我对AMD的看法，并使我120美元的股价目标面临危险。</blockquote></p><p> Softening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.</p><p><blockquote>CPU和图形芯片的平均售价疲软可能会成为煤矿中的金丝雀，并可能预示着AMD终端市场的提前疲软。终端市场疲软意味着AMD的收入增长将放缓，这可能会导致AMD利润估值的盈利乘数降低。我不认为AMD基于盈利被高估，但市场随时可能不同意我的评估。</blockquote></p><p> <b>Final thoughts</b></p><p><blockquote><b>最后的想法</b></blockquote></p><p> AMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.</p><p><blockquote>AMD报告第二季度收入增长和毛利率令人印象深刻。AMD上调指引和环比收入加速表明CPU和GPU的终端市场远强于预期。在平均售价上升的支持下，这可能会导致又一年的收入加速增长，AMD的毛利率持续扩大至50%。AMD的风险状况仍然严重偏向上行。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"source_url":"https://seekingalpha.com/article/4442955-amd-still-growing-still-undervalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135561812","content_text":"Summary\n\nAMD's margin gains are driven by growing strength in end markets.\nAMD raised its revenue guidance by $1.0B for FY 2021 and gross margins are edging closer to 50%.\nThe semiconductor firm could be a $6.0B free cash flow business next year, even if growth slows down.\nAMD's dollar sales growth is cheaper than Nvidia's and AMD might even grow faster.\n\nJay_Zynism/iStock via Getty Images\nAMD (AMD) made a splash yesterday after the semiconductor company reported growth and margins that were even better than what was expected. AMD’s revenue acceleration and strong gross margin expansion make a strong case for upside in the stock.\nWhy AMD is worth $120\nBefore I dive into AMD’s latestresults, let’s quickly recap what the firm’s guidance was for the last quarter. For Q2’21, AMD expected a minimum of $3.5B in revenues with “high case” guidance implying 7% revenue growth Q/Q and a gross margin of 47%.\nI expected AMD’s revenues to hit the high end of guidance ($3.7B), to have a minimum free cash flow of $895M (8% Q/Q growth) and a free cash flow margin of 24%. Given the acceleration of sales in higher-priced Ryzen desktop and notebook processors and GPUs as well as higher average selling prices/ASPs driven by broad-based strength in end markets, I expected AMD to beat its own margin guidance and report a gross margin of 48% for Q2’21. I also predicted a refreshment of AMD’s gross margin guidance due to strength in CPU and GPU ASPs. I laid out my forecast for AMD’s Q2’21 earnings in detail inAMD: On The Road To $5 Billion In Annual Free Cash Flow.\nTurning to AMD’s actual results, the semiconductor firm proved once more that it is firing on all cylinders. AMD’s Q2’21 revenues were $3,850M, $150M above the high-end of guidance and up 12% Q/Q, with revenue momentum continuing in both Graphics/Computing and Enterprise markets. Graphics/Computing revenues increased 7% Q/Q to $2,250M because of higher client and graphic processor sales as well as strengthening ASPs. Enterprise, which has become the driver of AMD’s sales growth in recent quarters, saw Q2'21 revenues of $1.6B, up 19% Q/Q. Enterprise revenues continued to accelerate in Q2'21, after AMD recorded 5% Q/Q revenue growth in Q1'21.\n(Source:AMD)\nThe most interesting revelation of AMD’s Q2’21 earnings, however, was the trend in gross margins. AMD's gross margin jumped 4 PP to 48%, 1 PP above guidance because of a better mix of higher-priced Ryzen processors (both mobile and desktop) and Radeon graphic cards. The uptick in gross margins in Q2’21 marked the third straight quarter of margin expansion for AMD and I don’t believe AMD has seen the end of this trend yet.\n(Source:AMD)\nTurning to cash flow.\nAMD reported cash flow from operating activities of $952M and free cash flow of $888M, $7M short of my expectation, but still almost six times more than a year ago. As AMD continues to see strong revenue growth tailwinds in both Computing/Graphics and Enterprise end markets, I believe AMD could grow its free cash flow margin to 30% by the end of next year. AMD raised its revenue guidance for FY 2021 (discussed later) by $1.0B which means I am also refreshing my free cash flow expectations for this year and next year.\nAMD expects to have revenues of $15.6B this year. Assuming a stable free cash flow margin of 23-24%, AMD is looking at free cash flow of $3.6B to $3.7B. Revenue estimates for next year are not refreshed yet, but AMD should have revenues of at least $20B in FY 2022 (assuming 25% Y/Y growth), implying free cash flow of $4.6B to $4.8B next year… and these estimates do not account for the possibility that AMD’s 3rd-gen EPYC Milan-powered server processors and higher-priced GPUs improve AMD’s free cash flow margin. A 30% free cash flow margin next year implies a free cash flow of $6.0B.\n(Source: Author)\n\n\n\n\n\nAMD is guiding for $4.1B in revenues +/- $100 million and the firm refreshed its FY 2021 revenue and gross margin guidance (as predicted). AMD now expects 60% revenue growth for FY 2021 (before 50%) and a gross margin of 48% (before 47%). Assuming 60% revenue growth, AMD is now looking at full year revenues of $15.6B (before $14.6B), so AMD's new guidance calls for $1.0B in additional revenues that were so far not priced into AMD’s market value.\n(Source:AMD)\nAMD’s higher gross margins and sales guidance create a potent force for the firm’s stock to revalue higher. Because of the recent dip in AMD’s shares and the addition of $1.0B in revenues, AMD’s dollar sales growth has become even cheaper after earnings. AMD’s dollar sales growth is valued lower than Nvidia’s and AMD is growing potentially at a faster rate: AMD's revenue guidance calls for 60% Y/Y growth and estimates for Nvidia imply \"only\" 49% Y/Y revenue growth for FY 2021. AMD has a market-capitalization-to-earnings ratio of 42.5 which is low for a firm that grows revenues 60% and that has a gross margin closing in on 50%.\n(Source: Author)\n\n\n\n\n\nNvidia’s P-E ratio based on an FY 2022 EPS of $17.29 is 44.5. If AMD earnings growth (FY 2022 EPS of $2.71) was valued the same as Nvidia’s, AMD’s fair price would be $120 ($2.71 x 44.5 earnings multiplier factor), indicating 17% upside.\nChallenges to my price target\nThe biggest opportunities and the biggest risks for AMD are tied to gross margins. AMD is having a year of strong revenue acceleration and margin growth, which is the chief reason why I believe AMD can revalue higher. But gross margins can't grow 3-4 PP every quarter. If AMD's gross margin expansion slows, or worse, gross margins drop back to 40%, decreasing stock returns for AMD are likely. A reversal in the gross margin trend would change my opinion on AMD and put my $120 stock price target in jeopardy.\nSoftening ASPs for CPUs and graphic chips are likely going to be the canary in the coal mine and could indicate weakening end markets for AMD ahead of time. Softer end markets imply AMD's revenue growth will slow which could result in a lower earnings multiplier factor by which AMD's profits are valued. I don't believe AMD is overvalued based on earnings, but the market may disagree with my assessment at any time.\nFinal thoughts\nAMD reported impressive revenue growth and gross margins for Q2. AMD's raised guidance and Q/Q revenue acceleration indicate that end markets for CPUs and GPUs are a lot stronger than expected. This could lead to another year of revenue acceleration and a continual expansion of AMD’s gross margin to 50%, supported by rising ASPs. AMD's risk profile is still heavily skewed to the upside.","news_type":1,"symbols_score_info":{"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183586815,"gmtCreate":1623335990937,"gmtModify":1634034418706,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/183586815","repostId":"1193863762","repostType":4,"repost":{"id":"1193863762","kind":"news","pubTimestamp":1623334800,"share":"https://www.laohu8.com/m/news/1193863762?lang=zh_CN&edition=full","pubTime":"2021-06-10 22:20","market":"us","language":"en","title":"Global Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022<blockquote>全球半导体年销售额预计2021年增长19.7%，2022年增长8.8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1193863762","media":"seekingalpha","summary":"(June 10) Semiconductor stocks rose in morning trading.\nRelated: Semiconductor Watchlist: Jim Cramer","content":"<p>(June 10)&nbsp;Semiconductor&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;morning&nbsp;trading.</p><p><blockquote>（6月10日）半导体股早盘走高。</blockquote></p><p> <a href=\"https://laohu8.com/NW/1163875762\" target=\"_blank\"><b>Related:&nbsp;Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom</b></a><b></b></p><p><blockquote><a href=\"https://laohu8.com/NW/1163875762\" target=\"_blank\"><b>相关：半导体观察名单：吉姆·克莱默表示将拥有英伟达、AMD和博通</b></a><b></b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/eb703ee8165d2dc48c5550db47dfebc7\" tg-width=\"303\" tg-height=\"363\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to World Semiconductor Trade Statistics estimates, the global semiconductor market will rise from 6.8% in 2020 to 19.7% thisyear to ~$527B.</p><p><blockquote>根据世界半导体贸易统计估计，全球半导体市场将从2020年的6.8%上升到今年的19.7%，达到约527B美元。</blockquote></p><p> The most significant growth contributors are Memory with 31.7%, followed by Sensors with 22.4% and, Analog with 21.7%. All other major product categories are also expected to show double-digit growth rates, except Optoelectronics with 9.8% and MOS Micro with 8.1%.</p><p><blockquote>最重要的增长贡献者是内存，占31.7%，其次是传感器，占22.4%，模拟占21.7%。除光电9.8%和MOS微8.1%外，所有其他主要产品类别预计也将呈现两位数的增长率。</blockquote></p><p> In 2021, Asia Pacific (incl. China) is forecasted to show the most robust growth rate with 23.5%, followed by Europe with 21.1%, Japan 12.7%, and the Americas with 11.1%.</p><p><blockquote>2021年，亚太地区（包括中国）的增长率预计最强劲，为23.5%，其次是欧洲，为21.1%，日本为12.7%，美洲为11.1%。</blockquote></p><p> For 2022, the global semiconductor market is projected to grow by 8.8% to $573B, driven by double-digit growth of the Memory category. All regions are expected again to show favorable growth rates.</p><p><blockquote>2022年，在内存类别两位数增长的推动下，全球半导体市场预计将增长8.8%，达到5730亿美元。预计所有地区都将再次显示出良好的增长率。</blockquote></p><p> Related stocks YTD returns: NXP Semiconductor(NASDAQ:NXPI)&nbsp;+24.7%, On Semiconducter(NASDAQ:ON)&nbsp;+14.85%, Intel(NASDAQ:INTC)&nbsp;+14.4%,&nbsp; and, TSMC(NYSE:TSM)&nbsp;+6.3%.</p><p><blockquote>相关股票年初至今回报率：恩智浦半导体（纳斯达克：NXPI）+24.7%、安森美半导体（纳斯达克：ON）+14.85%、英特尔（纳斯达克：INTC）+14.4%、台积电（纽约证券交易所：TSM）+6.3%。</blockquote></p><p> ETFs:SMH,SOXL,SOXX,XSD,USD,SOXS,PSI,FTXL,SSG.</p><p><blockquote>ETF：SMH、SOXL、SOXX、XSD、USD、SOXS、PSI、FTXL、SSG。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022<blockquote>全球半导体年销售额预计2021年增长19.7%，2022年增长8.8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal Semiconductor annual sales projected to increase 19.7% in 2021, 8.8% in 2022<blockquote>全球半导体年销售额预计2021年增长19.7%，2022年增长8.8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-06-10 22:20</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(June 10)&nbsp;Semiconductor&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;morning&nbsp;trading.</p><p><blockquote>（6月10日）半导体股早盘走高。</blockquote></p><p> <a href=\"https://laohu8.com/NW/1163875762\" target=\"_blank\"><b>Related:&nbsp;Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom</b></a><b></b></p><p><blockquote><a href=\"https://laohu8.com/NW/1163875762\" target=\"_blank\"><b>相关：半导体观察名单：吉姆·克莱默表示将拥有英伟达、AMD和博通</b></a><b></b></blockquote></p><p> <img src=\"https://static.tigerbbs.com/eb703ee8165d2dc48c5550db47dfebc7\" tg-width=\"303\" tg-height=\"363\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> According to World Semiconductor Trade Statistics estimates, the global semiconductor market will rise from 6.8% in 2020 to 19.7% thisyear to ~$527B.</p><p><blockquote>根据世界半导体贸易统计估计，全球半导体市场将从2020年的6.8%上升到今年的19.7%，达到约527B美元。</blockquote></p><p> The most significant growth contributors are Memory with 31.7%, followed by Sensors with 22.4% and, Analog with 21.7%. All other major product categories are also expected to show double-digit growth rates, except Optoelectronics with 9.8% and MOS Micro with 8.1%.</p><p><blockquote>最重要的增长贡献者是内存，占31.7%，其次是传感器，占22.4%，模拟占21.7%。除光电9.8%和MOS微8.1%外，所有其他主要产品类别预计也将呈现两位数的增长率。</blockquote></p><p> In 2021, Asia Pacific (incl. China) is forecasted to show the most robust growth rate with 23.5%, followed by Europe with 21.1%, Japan 12.7%, and the Americas with 11.1%.</p><p><blockquote>2021年，亚太地区（包括中国）的增长率预计最强劲，为23.5%，其次是欧洲，为21.1%，日本为12.7%，美洲为11.1%。</blockquote></p><p> For 2022, the global semiconductor market is projected to grow by 8.8% to $573B, driven by double-digit growth of the Memory category. All regions are expected again to show favorable growth rates.</p><p><blockquote>2022年，在内存类别两位数增长的推动下，全球半导体市场预计将增长8.8%，达到5730亿美元。预计所有地区都将再次显示出良好的增长率。</blockquote></p><p> Related stocks YTD returns: NXP Semiconductor(NASDAQ:NXPI)&nbsp;+24.7%, On Semiconducter(NASDAQ:ON)&nbsp;+14.85%, Intel(NASDAQ:INTC)&nbsp;+14.4%,&nbsp; and, TSMC(NYSE:TSM)&nbsp;+6.3%.</p><p><blockquote>相关股票年初至今回报率：恩智浦半导体（纳斯达克：NXPI）+24.7%、安森美半导体（纳斯达克：ON）+14.85%、英特尔（纳斯达克：INTC）+14.4%、台积电（纽约证券交易所：TSM）+6.3%。</blockquote></p><p> ETFs:SMH,SOXL,SOXX,XSD,USD,SOXS,PSI,FTXL,SSG.</p><p><blockquote>ETF：SMH、SOXL、SOXX、XSD、USD、SOXS、PSI、FTXL、SSG。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3704878-global-semiconductor-annual-sales-projected-to-increase-about-20-percentage-in-2021-and-9-percentage-in-2022\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ON":"安森美半导体","NXPI":"恩智浦","INTC":"英特尔","TSM":"台积电"},"source_url":"https://seekingalpha.com/news/3704878-global-semiconductor-annual-sales-projected-to-increase-about-20-percentage-in-2021-and-9-percentage-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193863762","content_text":"(June 10) Semiconductor stocks rose in morning trading.\nRelated: Semiconductor Watchlist: Jim Cramer Says to Own Nvidia, AMD and Broadcom\n\nAccording to World Semiconductor Trade Statistics estimates, the global semiconductor market will rise from 6.8% in 2020 to 19.7% thisyear to ~$527B.\nThe most significant growth contributors are Memory with 31.7%, followed by Sensors with 22.4% and, Analog with 21.7%. All other major product categories are also expected to show double-digit growth rates, except Optoelectronics with 9.8% and MOS Micro with 8.1%.\nIn 2021, Asia Pacific (incl. China) is forecasted to show the most robust growth rate with 23.5%, followed by Europe with 21.1%, Japan 12.7%, and the Americas with 11.1%.\nFor 2022, the global semiconductor market is projected to grow by 8.8% to $573B, driven by double-digit growth of the Memory category. All regions are expected again to show favorable growth rates.\nRelated stocks YTD returns: NXP Semiconductor(NASDAQ:NXPI) +24.7%, On Semiconducter(NASDAQ:ON) +14.85%, Intel(NASDAQ:INTC) +14.4%,  and, TSMC(NYSE:TSM) +6.3%.\nETFs:SMH,SOXL,SOXX,XSD,USD,SOXS,PSI,FTXL,SSG.","news_type":1,"symbols_score_info":{"INTC":0.9,"NXPI":0.9,"ON":0.9,"TSM":0.9}},"isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891182524,"gmtCreate":1628349184668,"gmtModify":1633751515667,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/891182524","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899971972,"gmtCreate":1628155634196,"gmtModify":1633753094090,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/899971972","repostId":"1129515398","repostType":4,"repost":{"id":"1129515398","kind":"news","pubTimestamp":1628151873,"share":"https://www.laohu8.com/m/news/1129515398?lang=zh_CN&edition=full","pubTime":"2021-08-05 16:24","market":"us","language":"en","title":"Here's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129515398","media":"Motley Fool","summary":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket tra","content":"<p>  Investors could soon have 200 million reasons to celebrate.  <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p><p><blockquote>投资者很快就会有2亿个理由庆祝。<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>继昨天飙升18%后，盘前交易中股价上涨超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p><p><blockquote>本公司之股份<b>Novavax</b>在这家生物技术公司达成向欧盟供应多达2亿剂冠状病毒候选疫苗的协议后，周三股价飙升18.7%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p><p><blockquote>如果Novavax的疫苗获得监管批准，欧盟委员会（EC）将购买多达1亿剂疫苗。该协议还赋予欧盟委员会到2023年额外购买1亿剂疫苗的选择权。</blockquote></p><p> Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p><p><blockquote>Novavax希望在第三季度完成其药物向欧洲药品管理局的滚动提交。Novavax首席执行官斯坦利·埃尔克(Stanley Erck)在一份新闻稿中表示：“我们试验的临床数据显示，针对令人担忧的变种和感兴趣的变种具有强大的功效，我们相信我们的候选疫苗将在帮助控制欧盟和世界其他地区的疫情方面发挥关键作用。”</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p><p><blockquote>Novavax在英国的一项3期临床试验中显示出针对COVID-19的总体疗效为89.7%。在该研究的大约15,000名参与者中，该药物的耐受性也普遍良好。卫生官员表示，在病例数以惊人的速度增加之际，该疫苗可能有助于减缓COVID-19的传播。</blockquote></p><p> \"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p><p><blockquote>欧盟委员会主席乌尔苏拉·冯德莱恩表示：“随着新的冠状病毒变种在欧洲和世界各地传播，与一家已经成功测试其针对这些变种的疫苗的公司签订的这份新合同是保护我们人口的额外保障。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Novavax Stock Soared on Wednesday<blockquote>这就是Novavax股价周三飙升的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-08-05 16:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  Investors could soon have 200 million reasons to celebrate.  <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;jumped&nbsp;over&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;after&nbsp;soaring&nbsp;18%&nbsp;yesterday.</p><p><blockquote>投资者很快就会有2亿个理由庆祝。<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>继昨天飙升18%后，盘前交易中股价上涨超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35aa95873d6840e6e61aa943b021597f\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of<b>Novavax</b>&nbsp;surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.</p><p><blockquote>本公司之股份<b>Novavax</b>在这家生物技术公司达成向欧盟供应多达2亿剂冠状病毒候选疫苗的协议后，周三股价飙升18.7%。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.</p><p><blockquote>如果Novavax的疫苗获得监管批准，欧盟委员会（EC）将购买多达1亿剂疫苗。该协议还赋予欧盟委员会到2023年额外购买1亿剂疫苗的选择权。</blockquote></p><p> Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.</p><p><blockquote>Novavax希望在第三季度完成其药物向欧洲药品管理局的滚动提交。Novavax首席执行官斯坦利·埃尔克(Stanley Erck)在一份新闻稿中表示：“我们试验的临床数据显示，针对令人担忧的变种和感兴趣的变种具有强大的功效，我们相信我们的候选疫苗将在帮助控制欧盟和世界其他地区的疫情方面发挥关键作用。”</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.</p><p><blockquote>Novavax在英国的一项3期临床试验中显示出针对COVID-19的总体疗效为89.7%。在该研究的大约15,000名参与者中，该药物的耐受性也普遍良好。卫生官员表示，在病例数以惊人的速度增加之际，该疫苗可能有助于减缓COVID-19的传播。</blockquote></p><p> \"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.&nbsp;</p><p><blockquote>欧盟委员会主席乌尔苏拉·冯德莱恩表示：“随着新的冠状病毒变种在欧洲和世界各地传播，与一家已经成功测试其针对这些变种的疫苗的公司签订的这份新合同是保护我们人口的额外保障。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/04/heres-why-novavax-stock-soared-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129515398","content_text":"Investors could soon have 200 million reasons to celebrate.\n\nNovavax jumped over 4% in premarket trading after soaring 18% yesterday.\n\nWhat happened\nShares ofNovavax surged 18.7% on Wednesday after thebiotechnologycompany struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU.\nSo what\nShould Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. The agreement also gives the EC the option to buy an additional 100 million doses by 2023.\nNovavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter. \"With clinical data from our trials showing strong efficacy against Variants of Concern and Variants of Interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,\" Novavax CEO Stanley Erck said in a press release.\nNow what\nNovavax demonstrated overall efficacy of 89.7% against COVID-19 in a phase 3 clinical trial in the U.K. The drug was also generally well-tolerated among the study's roughly 15,000 participants. Health officials say the vaccine could help to slow the spread of COVID-19 at a time when case counts are mounting at an alarming rate.\n\"As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population,\" European Commission President Ursula von der Leyen said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":859021205,"gmtCreate":1634641639710,"gmtModify":1634641747081,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859021205","repostId":"1111431743","repostType":4,"repost":{"id":"1111431743","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634637193,"share":"https://www.laohu8.com/m/news/1111431743?lang=zh_CN&edition=full","pubTime":"2021-10-19 17:53","market":"us","language":"en","title":"Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111431743","media":"Benzinga","summary":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo","content":"<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-10-19 17:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Chinese e-commerce giant&nbsp;<b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed&nbsp;plans&nbsp;to develop an in-house processor that would be used to power its&nbsp;cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b>&nbsp;The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has&nbsp;been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;The semiconductor foray replicates similar moves from rival computing players such as&nbsp;<b>Huawei Technologies</b>&nbsp;and&nbsp;<b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in&nbsp;the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to&nbsp;smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b>&nbsp;Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111431743","content_text":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.\nWhat Happened: The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.\nThe design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.\nWhy It Matters: The semiconductor foray replicates similar moves from rival computing players such as Huawei Technologies and Amazon.com Inc.\nAlibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.\nThe Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.\nPrice Action: Alibaba shares closed 0.68% lower at $166.82 a share on Monday.","news_type":1,"symbols_score_info":{"BABA":0.9,"09988":0.9}},"isVote":1,"tweetType":1,"viewCount":2738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862950901,"gmtCreate":1632832381619,"gmtModify":1632832381719,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862950901","repostId":"2170670597","repostType":4,"isVote":1,"tweetType":1,"viewCount":3714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":114580397,"gmtCreate":1623079650319,"gmtModify":1634037159884,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114580397","repostId":"1196162025","repostType":4,"isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130668264,"gmtCreate":1621539767258,"gmtModify":1634188331666,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/130668264","repostId":"2136010949","repostType":4,"isVote":1,"tweetType":1,"viewCount":1128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354946884,"gmtCreate":1617122596648,"gmtModify":1634522521026,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy Buy buy","listText":"Buy Buy buy","text":"Buy Buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/354946884","repostId":"2123291766","repostType":4,"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":"1165830356","repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b>&nbsp;has&nbsp;entered into agreements&nbsp;with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul>  <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li>  <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li>  <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease &amp; lower manufacturing cost, and potential for improved patient safety.</li>  <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li>  <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li>  <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li>  <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li>  <li><b>Price Action:</b>&nbsp;BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":2502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447407,"gmtCreate":1636024166653,"gmtModify":1636024166821,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447407","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohu8.com/m/news/1101079537?lang=zh_CN&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernamRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&amp;D)以及销售、一般和行政(SG&amp;A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&amp;A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul>  <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul>  <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc.&nbsp;today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul>  <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li>  <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li>  <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li>  <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul>  <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li>  <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li>  <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul>  <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li>  <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li>  <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul>  <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li>  <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li>  <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li>  <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li>  <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li>  <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna&nbsp;continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernamRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul>  <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li>  <li></li>  <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li>  <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li>  <li><b>2021 Research &amp; Development (R&amp;D) and Selling, General &amp; Administrative (SG&amp;A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&amp;D and SG&amp;A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li>  <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li>  <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li>  <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&amp;D)以及销售、一般和行政(SG&amp;A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&amp;A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul>  <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li>  <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li>  <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":117506278,"gmtCreate":1623147977094,"gmtModify":1634036453521,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/117506278","repostId":"1136550999","repostType":4,"isVote":1,"tweetType":1,"viewCount":549,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347687423,"gmtCreate":1618493700662,"gmtModify":1634292571818,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347687423","repostId":"1148801353","repostType":4,"repost":{"id":"1148801353","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1618493511,"share":"https://www.laohu8.com/m/news/1148801353?lang=zh_CN&edition=full","pubTime":"2021-04-15 21:31","market":"us","language":"en","title":"Stocks jump at the open as Coinbase rises, Americans go shopping<blockquote>随着Coinbase上涨，美国人去购物，股市开盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1148801353","media":"Tiger Newspress","summary":"(April 15) U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate r","content":"<p>(April 15)&nbsp;U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.</p><p><blockquote>（四月十五日）美国。由于一系列强劲的经济报告和企业业绩，周四股市高开。</blockquote></p><p>The Dow Jones Industrial Average&nbsp;added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&amp;P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index&nbsp;was up 122 points or 0.9%, near 13,980.</p><p><blockquote>根据初步估计，道琼斯工业平均指数上涨177点，涨幅0.5%，开盘接近33,908点；标准普尔500指数上涨25点，涨幅0.6%，开盘接近4,149点。纳斯达克综合指数上涨122点或0.9%，接近13,980点。</blockquote></p><p>First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.</p><p><blockquote>美国劳工部周四上午表示，最近一周首次申请失业救济人数大幅下降，随着美国人花掉刺激支票，3月份零售额飙升近10%。</blockquote></p><p>Shares of Coinbase Global Inc.&nbsp;gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc.&nbsp;beat analyst expectations.</p><p><blockquote>在散户和机构投资者的推动下，Coinbase Global Inc.的股价在加密货币交易所交易的第二天上涨，花旗集团等公司的盈利超出了分析师的预期。</blockquote></p><p>A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.</p><p><blockquote>周四另一份报告显示，首次申请失业保险的人数降至2020年3月以来的最低水平。劳工部报告称，截至4月10日当周，新申请失业救济人数为576,000人。道琼斯调查的经济学家预计总数为71万人。</blockquote></p><p>Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.</p><p><blockquote>消费零食和饮料制造商百事可乐表示上季度销售额增长近7%，超出预期，该公司股价上涨0.6%。</blockquote></p><p>Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.</p><p><blockquote>道指成分股成员联合健康(UnitedHealth)的股价上涨1%，此前该健康保险公司的业绩超过华尔街，并且该健康保险公司上调了2021年的指引。</blockquote></p><p>Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.</p><p><blockquote>科技股早盘从周二的跌幅中反弹，特斯拉股价上涨约1%。新上市的加密货币交易所Coinbase在交易首日被曝出Ark Invest的Cathie Woodload股价上涨9%。</blockquote></p><p>On Tuesday, the Food and Drug Administration called for a pause&nbsp;in administering J&amp;J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.</p><p><blockquote>周二，在美国有六人出现一种涉及血栓的罕见疾病后，美国食品和药物管理局呼吁暂停注射强生的Covid-19疫苗。这一消息在本周早些时候引发了重新开放游戏的抛售，但预计不会对美国疫苗推出的步伐产生重大影响。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks jump at the open as Coinbase rises, Americans go shopping<blockquote>随着Coinbase上涨，美国人去购物，股市开盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks jump at the open as Coinbase rises, Americans go shopping<blockquote>随着Coinbase上涨，美国人去购物，股市开盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-15 21:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(April 15)&nbsp;U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.</p><p><blockquote>（四月十五日）美国。由于一系列强劲的经济报告和企业业绩，周四股市高开。</blockquote></p><p>The Dow Jones Industrial Average&nbsp;added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&amp;P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index&nbsp;was up 122 points or 0.9%, near 13,980.</p><p><blockquote>根据初步估计，道琼斯工业平均指数上涨177点，涨幅0.5%，开盘接近33,908点；标准普尔500指数上涨25点，涨幅0.6%，开盘接近4,149点。纳斯达克综合指数上涨122点或0.9%，接近13,980点。</blockquote></p><p>First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.</p><p><blockquote>美国劳工部周四上午表示，最近一周首次申请失业救济人数大幅下降，随着美国人花掉刺激支票，3月份零售额飙升近10%。</blockquote></p><p>Shares of Coinbase Global Inc.&nbsp;gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc.&nbsp;beat analyst expectations.</p><p><blockquote>在散户和机构投资者的推动下，Coinbase Global Inc.的股价在加密货币交易所交易的第二天上涨，花旗集团等公司的盈利超出了分析师的预期。</blockquote></p><p>A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.</p><p><blockquote>周四另一份报告显示，首次申请失业保险的人数降至2020年3月以来的最低水平。劳工部报告称，截至4月10日当周，新申请失业救济人数为576,000人。道琼斯调查的经济学家预计总数为71万人。</blockquote></p><p>Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.</p><p><blockquote>消费零食和饮料制造商百事可乐表示上季度销售额增长近7%，超出预期，该公司股价上涨0.6%。</blockquote></p><p>Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.</p><p><blockquote>道指成分股成员联合健康(UnitedHealth)的股价上涨1%，此前该健康保险公司的业绩超过华尔街，并且该健康保险公司上调了2021年的指引。</blockquote></p><p>Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.</p><p><blockquote>科技股早盘从周二的跌幅中反弹，特斯拉股价上涨约1%。新上市的加密货币交易所Coinbase在交易首日被曝出Ark Invest的Cathie Woodload股价上涨9%。</blockquote></p><p>On Tuesday, the Food and Drug Administration called for a pause&nbsp;in administering J&amp;J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.</p><p><blockquote>周二，在美国有六人出现一种涉及血栓的罕见疾病后，美国食品和药物管理局呼吁暂停注射强生的Covid-19疫苗。这一消息在本周早些时候引发了重新开放游戏的抛售，但预计不会对美国疫苗推出的步伐产生重大影响。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148801353","content_text":"(April 15) U.S. stocks opened higher Thursday amid a raft of strong economic reports and corporate results.The Dow Jones Industrial Average added 177 points, or 0.5%, according to preliminary estimates, to open near 33,908, while the S&P 500gained 25 points or 0.6%, to start trading near 4,149. The Nasdaq Composite index was up 122 points or 0.9%, near 13,980.First-time filings for jobless benefits fell sharply in the most recent week, the Labor Department said Thursday morning, and retail sales rocketed nearly 10% in March as Americans spent their stimulus checks.Shares of Coinbase Global Inc. gained on the second day of trading for the cryptocurrency exchange, boosted by both retail and institutional investors alike, and earnings for companies like Citigroup Inc. beat analyst expectations.A separate report on Thursday showed that first-time filings for unemployment insurance dropped to the lowest level since March 2020. The Labor Department reported 576,000 new jobless claims for the week ended April 10. Economists polled by Dow Jones expected a total of 710,000.Pepsi shares added 0.6% after the consumer snack and drink maker saidsales last quarter rose nearly 7%, topping estimates.Shares of UnitedHealth, a Dow member, gained 1% after results topped the Street and the health insurer raised guidance for 2021.Tech stocks rebounded from Tuesday losses in early trading with shares of Tesla up about 1%. Newly public crypto exchange Coinbase jumped 9% in early trading after it was revealed Ark Invest’s Cathie Woodloaded up on the first day of trading.On Tuesday, the Food and Drug Administration called for a pause in administering J&J’s Covid-19 vaccine aftersix people in the U.S. developed a rare disorderinvolving blood clots. The announcement triggered a sell-off in reopening plays earlier in the week, but is not expected to have a material impact on the pace of the U.S. vaccine rollout.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608690847,"gmtCreate":1638701123059,"gmtModify":1638701123059,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608690847","repostId":"2188528084","repostType":4,"isVote":1,"tweetType":1,"viewCount":3414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}